PHKG1
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A0A2R8Y4L2 | S95 | Sugiyama | HNRNPA1L3 HNRNPA1P48 | RPHKVDGRVVEPKRAVSREDsQRPDAHLTVKKIFVGGIKED |
| A5A3E0 | S1068 | Sugiyama | POTEF A26C1B | SLSTFQQMWISKQEyDEsGPsIVHRKCL_____________ |
| O60841 | S222 | Sugiyama | EIF5B IF2 KIAA0741 | KNQKNKPGPNIEsGNEDDDAsFKIKTVAQKKAEKKERERKK |
| O75569 | S18 | Sugiyama | PRKRA PACT RAX HSD-14 HSD14 | ___MSQSRHRAEAPPLEREDsGtFsLGKMITAKPGKTPIQV |
| O75937 | S81 | Sugiyama | DNAJC8 SPF31 HSPC315 HSPC331 | VLQIDPEVTDEEIKKRFRQLsILVHPDKNQDDADRAQKAFE |
| O95714 | S2928 | Sugiyama | HERC2 | ILLGRIRAEEEDLAAVPFLAsDNEEEEDEKGNSGsLIRKKA |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04075 | T37 | Sugiyama | ALDOA ALDA | sDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRR |
| P04406 | S312 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | sstFDAGAGIALNDHFVKLIsWyDNEFGysNRVVDLMAHMA |
| P04406 | S321 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsKE______ |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P06737 | S15 | SIGNOR | PYGL | ______MAKPLTDQEKRRQIsIRGIVGVENVAELKKSFNRH |
| P06899 | S39 | Sugiyama | H2BC11 H2BFR HIST1H2BJ | VTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGISSKA |
| P07195 | S303 | Sugiyama | LDHB | GIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsADt |
| P07437 | S75 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | tGGKyVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| P07900 | S52 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | LIINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDs |
| P09651 | S95 | Sugiyama | HNRNPA1 HNRPA1 | RPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| P0CG38 | S1068 | Sugiyama | POTEI | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P0CG39 | S1031 | Sugiyama | POTEJ | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P0DPH7 | S48 | Sugiyama | TUBA3C TUBA2 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| P10412 | S55 | Sugiyama | H1-4 H1F4 HIST1H1E | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P10636 | S554 | SIGNOR|EPSD | MAPT MAPTL MTBT1 TAU | tPPTREPKKVAVVRtPPKsPssAKSRLQTAPVPMPDLKNVK |
| P10636 | S579 | SIGNOR|EPSD | MAPT MAPTL MTBT1 TAU | RLQTAPVPMPDLKNVKsKIGstENLKHQPGGGKVQIINKKL |
| P10636 | S602 | SIGNOR | MAPT MAPTL MTBT1 TAU | NLKHQPGGGKVQIINKKLDLsNVQsKCGsKDNIKHVPGGGs |
| P10636 | S622 | SIGNOR | MAPT MAPTL MTBT1 TAU | sNVQsKCGsKDNIKHVPGGGsVQIVyKPVDLSKVTsKCGsL |
| P10636 | S669 | SIGNOR | MAPT MAPTL MTBT1 TAU | PGGGQVEVKSEKLDFKDRVQsKIGsLDNITHVPGGGNKKIE |
| P11142 | S40 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P11217 | S15 | SIGNOR | PYGM | ______MsRPLSDQEKRKQIsVRGLAGVENVtELKKNFNRH |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P14618 | T50 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | MCRLDIDsPPItARNtGIICtIGPAsRsVEtLKEMIKsGMN |
| P14625 | S514 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | LGVIEDHsNRtRLAKLLRFQssHHPtDItsLDQyVERMKEK |
| P15735 | S35 | Sugiyama | PHKG2 | AAAKEFYQKYDPKDVIGRGVssVVRRCVHRATGHEFAVKIM |
| P15735 | S36 | Sugiyama | PHKG2 | AAKEFYQKYDPKDVIGRGVssVVRRCVHRATGHEFAVKIME |
| P16070 | S71 | Sugiyama | CD44 LHR MDU2 MDU3 MIC4 | DLCKAFNSTLPTMAQMEKALsIGFEtCRyGFIEGHVVIPRI |
| P16402 | S56 | Sugiyama | H1-3 H1F3 HIST1H1D | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P16403 | S55 | Sugiyama | H1-2 H1F2 HIST1H1C | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P17066 | S42 | Sugiyama | HSPA6 HSP70B' | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P20618 | S162 | Sugiyama | PSMB1 PSC5 | DEEGKGAVysFDPVGsyQRDsFKAGGSASAMLQPLLDNQVG |
| P23527 | S39 | Sugiyama | H2BC17 H2BFH H2BFN HIST1H2BO | VTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGISSKA |
| P23588 | S122 | Sugiyama | EIF4B | NLPyDVTEESIKEFFRGLNIsAVRLPREPsNPERLKGFGyA |
| P26373 | S181 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | YKKEKARVItEEEKNFKAFAsLRMARANARLFGIRAKRAKE |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P26373 | S97 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | sLEELRVAGIHKKVARTIGIsVDPRRRNKstEsLQANVQRL |
| P27797 | S52 | Sugiyama | CALR CRTC | GWtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDA |
| P29692 | S44 | Sugiyama | EEF1D EF1D | RFyEQMNGPVAGAsRQENGAsVILRDIARARENIQKsLAGs |
| P30050 | S138 | Sugiyama | RPL12 | HRSLARELsGtIKEILGtAQsVGCNVDGRHPHDIIDDINsG |
| P30101 | T485 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | KKyEGGRELsDFIsyLQREAtNPPVIQEEKPKKKKKAQEDL |
| P31327 | S205 | Sugiyama | CPS1 | FEGQPVDFVDPNKQNLIAEVstKDVKVYGKGNPTKVVAVDC |
| P32119 | T142 | Sugiyama | PRDX2 NKEFB TDPX1 | EGIAYRGLFIIDGKGVLRQItVNDLPVGRsVDEALRLVQAF |
| P33778 | S39 | Sugiyama | H2BC3 H2BFF HIST1H2BB | ITKAQKKDGKKRKRsRKEsysIyVyKVLKQVHPDTGISSKA |
| P34931 | S42 | Sugiyama | HSPA1L | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P35579 | S1916 | Sugiyama | MYH9 | LQRELEDAtEtADAMNREVssLKNKLRRGDLPFVVPRRMAR |
| P35579 | T1906 | Sugiyama | MYH9 | AQRANAsRRKLQRELEDAtEtADAMNREVssLKNKLRRGDL |
| P37108 | S25 | Sugiyama | SRP14 | EsEQFLtELTRLFQKCRTSGsVyItLKKYDGRTKPIPKKGt |
| P37802 | S163 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | LFsGDPNWFPKKSKENPRNFsDNQLQEGKNVIGLQMGtNRG |
| P38646 | S89 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | VMEGKQAKVLENAEGARttPsVVAFtADGERLVGMPAKRQA |
| P38646 | T116 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | DGERLVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKD |
| P42677 | S78 | Sugiyama | RPS27 MPS1 | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P46777 | S172 | Sugiyama | RPL5 MSTP030 | RTTTGNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNA |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P48741 | S42 | Sugiyama | HSPA7 HSP70B | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P50552 | S46 | Sugiyama | VASP | AGTGPQAFSRVQIyHNPTANsFRVVGRKMQPDQQVVINCAI |
| P50991 | S51 | Sugiyama | CCT4 CCTD SRB | AQIRFsNISAAKAVADAIRtsLGPKGMDKMIQDGKGDVtIt |
| P53999 | S118 | Sugiyama | SUB1 PC4 RPO2TC1 | PGRKGIsLNPEQWsQLKEQIsDIDDAVRKL___________ |
| P54652 | S41 | Sugiyama | HSPA2 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P60709 | S368 | Sugiyama | ACTB | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P60709 | S60 | Sugiyama | ACTB | HQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEHGIVTNWD |
| P60709 | T318 | Sugiyama | ACTB | VLsGGttMyPGIADRMQKEItALAPstMKIKIIAPPERKYs |
| P60709 | T324 | Sugiyama | ACTB | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P60709 | Y53 | Sugiyama | ACTB | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEH |
| P61604 | S64 | Sugiyama | HSPE1 | AtVVAVGsGsKGKGGEIQPVsVKVGDKVLLPEyGGtKVVLD |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S148 | Sugiyama | YWHAE | YHRyLAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHP |
| P62263 | S139 | Sugiyama | RPS14 PRO2640 | LARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL________ |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62277 | S12 | Sugiyama | RPS13 | _________MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDD |
| P62736 | S62 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | HQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEHGIItNWD |
| P62736 | T320 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P62736 | T326 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P62736 | Y55 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P62899 | T26 | Sugiyama | RPL31 | KGGEKKKGRsAINEVVtREytINIHKRIHGVGFKKRAPRAL |
| P62917 | S14 | Sugiyama | RPL8 | _______MGRVIRGQRKGAGsVFRAHVKHRKGAARLRAVDF |
| P63220 | S68 | Sugiyama | RPS21 | GQFKtyAICGAIRRMGEsDDsILRLAKADGIVSKNF_____ |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P63261 | S368 | Sugiyama | ACTG1 ACTG | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P63261 | S60 | Sugiyama | ACTG1 ACTG | HQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEHGIVTNWD |
| P63261 | T318 | Sugiyama | ACTG1 ACTG | VLsGGttMyPGIADRMQKEItALAPstMKIKIIAPPERKYs |
| P63261 | T324 | Sugiyama | ACTG1 ACTG | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P63261 | Y53 | Sugiyama | ACTG1 ACTG | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIEH |
| P63267 | S61 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | HQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEHGIItNWD |
| P63267 | T319 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P63267 | T325 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P63267 | Y54 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P67809 | S209 | Sugiyama | YBX1 NSEP1 YB1 | RRRRFPPyyMRRPYGRRPQysNPPVQGEVMEGADNQGAGEQ |
| P68032 | S62 | Sugiyama | ACTC1 ACTC | HQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEHGIItNWD |
| P68032 | T320 | Sugiyama | ACTC1 ACTC | VLSGGtTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P68032 | T326 | Sugiyama | ACTC1 ACTC | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68032 | Y55 | Sugiyama | ACTC1 ACTC | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P68133 | S62 | Sugiyama | ACTA1 ACTA | HQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEHGIItNWD |
| P68133 | T320 | Sugiyama | ACTA1 ACTA | VMSGGTTMYPGIADRMQKEItALAPstMKIKIIAPPERKYS |
| P68133 | T326 | Sugiyama | ACTA1 ACTA | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68133 | Y55 | Sugiyama | ACTA1 ACTA | sIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIEH |
| P68363 | S48 | Sugiyama | TUBA1B | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| P83731 | S38 | Sugiyama | RPL24 | GRRYARTDGKVFQFLNAKCEsAFLSKRNPRQINWtVLyRRK |
| P83731 | S7 | Sugiyama | RPL24 | ______________MKVELCsFsGyKIYPGHGRRYARTDGK |
| P83731 | T83 | Sugiyama | RPL24 | QsEEIQKKRTRRAVKFQRAItGAsLADIMAKRNQKPEVRKA |
| P84098 | S12 | Sugiyama | RPL19 | _________MSMLRLQKRLAssVLRCGKKKVWLDPNEtNEI |
| P84098 | S122 | Sugiyama | RPL19 | LRRLLRRYRESKKIDRHMyHsLyLKVKGNVFKNKRILMEHI |
| Q06830 | T143 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | EGIsFRGLFIIDDKGILRQItVNDLPVGRsVDEtLRLVQAF |
| Q07021 | S210 | Sugiyama | C1QBP GC1QBP HABP1 SF2P32 | EDEVGQEDEAEsDIFsIREVsFQstGESEWKDTNYTLNTDS |
| Q13509 | S75 | Sugiyama | TUBB3 TUBB4 | SSHKYVPRAILVDLEPGtMDsVRSGAFGHLFRPDNFIFGQS |
| Q13885 | S75 | Sugiyama | TUBB2A TUBB2 | AGNKYVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| Q14568 | S52 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | LIINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDS |
| Q15080 | S67 | Sugiyama | NCF4 SH3PXD4 | TKGGSKYLIYRRYRQFHALQsKLEERFGPDSKSSALACTLP |
| Q15084 | S389 | Sugiyama | PDIA6 ERP5 P5 TXNDC7 | FALLKGsFsEQGINEFLRELsFGRGstAPVGGGAFPtIVER |
| Q15185 | S85 | Sugiyama | PTGES3 P23 TEBP | KHKRtDRsILCCLRKGEsGQsWPRLTKERAKLNWLsVDFNN |
| Q16778 | S39 | Sugiyama | H2BC21 H2BFQ HIST2H2BE | VTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGIssKA |
| Q16816 | S10 | Sugiyama | PHKG1 PHKG | ___________MTRDEALPDsHsAQDFYENYEPKEILGRGV |
| Q16816 | S12 | Sugiyama | PHKG1 PHKG | _________MTRDEALPDsHsAQDFYENYEPKEILGRGVss |
| Q16816 | S172 | Sugiyama | PHKG1 PHKG | KPENILLDDNMNIKLTDFGFsCQLEPGERLREVCGtPSYLA |
| Q16816 | S31 | SIGNOR|EPSD|Sugiyama | PHKG1 PHKG | HsAQDFYENYEPKEILGRGVssVVRRCIHKPTSQEyAVKVI |
| Q16816 | S32 | Sugiyama | PHKG1 PHKG | sAQDFYENYEPKEILGRGVssVVRRCIHKPTSQEyAVKVID |
| Q16816 | S381 | Sugiyama | PHKG1 PHKG | KGQQQNRAALFENtPKAVLLsLAEEDY______________ |
| Q16816 | S58 | Sugiyama | PHKG1 PHKG | IHKPTSQEyAVKVIDVtGGGsFSPEEVRELREATLKEVDIL |
| Q16816 | S82 | SIGNOR|EPSD | PHKG1 PHKG | EEVRELREATLKEVDILRKVsGHPNIIQLKDTYETNTFFFL |
| Q16816 | T187 | Sugiyama | PHKG1 PHKG | TDFGFsCQLEPGERLREVCGtPSYLAPEIIECSMNEDHPGy |
| Q16816 | T374 | Sugiyama | PHKG1 PHKG | IYGHWVKKGQQQNRAALFENtPKAVLLsLAEEDY_______ |
| Q16816 | T54 | Sugiyama | PHKG1 PHKG | VRRCIHKPTSQEyAVKVIDVtGGGsFSPEEVRELREATLKE |
| Q16816 | Y207 | Sugiyama | PHKG1 PHKG | tPSYLAPEIIECSMNEDHPGyGKEVDMWSTGVIMYTLLAGS |
| Q16816 | Y350 | Sugiyama | PHKG1 PHKG | REIVIRDPYALRPLRRLIDAyAFRIYGHWVKKGQQQNRAAL |
| Q32P51 | S95 | Sugiyama | HNRNPA1L2 HNRNPA1L | TPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| Q5M775 | S112 | Sugiyama | SPECC1 CYTSB NSP5 | SGTGAFTTTKRTGIPAPREFsVTVSRERsVPRGPSNPRKsV |
| Q6DN03 | S39 | Sugiyama | H2BC20P HIST2H2BC | VTKAQKKDGKKRKRSRKEsysIyVyKVLKRVHPDTGIWCKA |
| Q6DRA6 | S39 | Sugiyama | H2BC19P HIST2H2BD | VTKAQKKDGKKRKRSRKEsysIyVyKVLKRVHPDTGIWCKA |
| Q6PEY2 | S48 | Sugiyama | TUBA3E | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q6S8J3 | S1068 | Sugiyama | POTEE A26C1A POTE2 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q71U36 | S48 | Sugiyama | TUBA1A TUBA3 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q71UM5 | S78 | Sugiyama | RPS27L | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q8IWX8 | S904 | Sugiyama | CHERP DAN26 SCAF6 | KGVGVALDDPyENyRRNKsysFIARMKARDECK________ |
| Q8N257 | S39 | Sugiyama | H2BC26 H2BU1 HIST3H2BB | VTKAQKKDGKKRKRGRKEsysIyVyKVLKQVHPDTGIssKA |
| Q99613 | S754 | Sugiyama | EIF3C EIF3S8 | REHVVAASKAMKMGDWKTCHsFIINEKMNGKVWDLFPEADK |
| Q99848 | S270 | Sugiyama | EBNA1BP2 EBP2 | FGGKKKGSKWNtREsyDDVssFRAKTAHGRGLKRPGKKGSN |
| Q9BQE3 | S48 | Sugiyama | TUBA1C TUBA6 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q9BVA1 | S75 | Sugiyama | TUBB2B | tGNKYVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| Q9BYX7 | S368 | Sugiyama | POTEKP ACTBL3 FKSG30 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q9H788 | S315 | Sugiyama | SH2D4A PPP1R38 SH2A | LNSGAYPQKPLRNQGVVRtLsssAQEDIIRWFKEEQLPLRA |
| Q9NZL9 | S9 | Sugiyama | MAT2B TGR MSTP045 Nbla02999 UNQ2435/PRO4995 | ____________MVGREKELsIHFVPGsCRLVEEEVNIPNR |
| Q9UPQ0 | S377 | Sugiyama | LIMCH1 KIAA1102 | LREEDDKWQDDLARWKSRRRsVsQDLIKKEEERKKMEKLLA |
| Q9UQ35 | S2692 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | ERRSRSPRKPIDsLRDsRsLsysPVERRRPsPQPsPRDQQS |
| Q9Y2B0 | S55 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | VDELEWEIAQVDPKKTIQMGsFRINPDGsQsVVEVPyARsE |
| Q9Y3U8 | S91 | Sugiyama | RPL36 | KFIKKRVGTHIRAKRKREELsNVLAAMRKAAAKKD______ |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Signal Transduction | R-HSA-162582 | 1.366685e-13 | 12.864 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 9.410961e-11 | 10.026 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.046325e-09 | 8.980 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.387297e-08 | 7.858 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.322725e-08 | 7.479 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 7.348817e-08 | 7.134 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.094298e-07 | 6.961 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.094298e-07 | 6.961 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.012986e-07 | 6.994 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.382439e-07 | 6.859 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 9.377516e-07 | 6.028 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.104117e-06 | 5.957 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.325262e-06 | 5.878 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.588881e-06 | 5.799 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.636000e-06 | 5.786 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.590703e-06 | 5.798 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.889593e-06 | 5.539 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.023921e-06 | 5.519 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 8.495631e-06 | 5.071 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.027679e-05 | 4.988 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 1.376520e-05 | 4.861 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.760085e-05 | 4.754 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.075288e-05 | 4.683 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.989023e-05 | 4.524 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 3.429492e-05 | 4.465 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 4.464060e-05 | 4.350 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 6.289757e-05 | 4.201 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 6.638785e-05 | 4.178 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 9.339573e-05 | 4.030 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.206513e-04 | 3.918 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.338587e-04 | 3.873 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.671918e-04 | 3.777 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.211839e-04 | 3.655 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 2.976911e-04 | 3.526 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 3.291086e-04 | 3.483 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 3.406430e-04 | 3.468 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 4.343837e-04 | 3.362 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 4.599207e-04 | 3.337 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 4.921368e-04 | 3.308 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 5.029175e-04 | 3.299 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 5.333163e-04 | 3.273 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 5.578664e-04 | 3.253 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 6.330173e-04 | 3.199 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 6.839047e-04 | 3.165 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 7.008194e-04 | 3.154 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 6.884742e-04 | 3.162 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 7.596818e-04 | 3.119 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 8.120724e-04 | 3.090 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 8.431899e-04 | 3.074 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 8.731836e-04 | 3.059 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 9.794653e-04 | 3.009 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 9.788536e-04 | 3.009 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 1.140692e-03 | 2.943 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 9.937439e-04 | 3.003 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.267640e-03 | 2.897 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.523531e-03 | 2.817 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.495126e-03 | 2.825 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.540337e-03 | 2.812 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.572128e-03 | 2.804 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.648869e-03 | 2.783 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 1.634437e-03 | 2.787 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.597040e-03 | 2.797 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.724198e-03 | 2.763 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.759077e-03 | 2.755 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 1.843345e-03 | 2.734 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 2.038326e-03 | 2.691 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 2.066888e-03 | 2.685 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 2.066888e-03 | 2.685 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 2.324372e-03 | 2.634 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.204705e-03 | 2.657 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 2.294406e-03 | 2.639 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 2.206966e-03 | 2.656 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.302401e-03 | 2.638 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 2.345185e-03 | 2.630 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.416987e-03 | 2.617 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.623234e-03 | 2.581 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 2.704130e-03 | 2.568 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.750335e-03 | 2.561 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 2.840836e-03 | 2.547 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.963510e-03 | 2.528 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 2.975360e-03 | 2.526 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 3.079993e-03 | 2.511 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 3.210595e-03 | 2.493 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 3.046903e-03 | 2.516 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.210595e-03 | 2.493 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 3.250956e-03 | 2.488 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 3.369663e-03 | 2.472 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 3.384948e-03 | 2.470 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 3.416672e-03 | 2.466 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 4.020457e-03 | 2.396 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 3.819373e-03 | 2.418 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 3.823342e-03 | 2.418 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 3.983611e-03 | 2.400 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 3.794993e-03 | 2.421 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 3.958889e-03 | 2.402 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 3.823342e-03 | 2.418 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 3.927016e-03 | 2.406 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 3.806943e-03 | 2.419 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.794993e-03 | 2.421 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 4.290929e-03 | 2.367 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 4.334497e-03 | 2.363 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 4.504078e-03 | 2.346 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 4.504078e-03 | 2.346 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 4.504078e-03 | 2.346 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 4.674270e-03 | 2.330 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 4.504078e-03 | 2.346 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 4.399518e-03 | 2.357 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.707476e-03 | 2.327 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.707476e-03 | 2.327 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 4.779318e-03 | 2.321 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 4.798884e-03 | 2.319 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 4.833770e-03 | 2.316 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 4.833770e-03 | 2.316 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 5.822853e-03 | 2.235 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 5.975234e-03 | 2.224 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 6.268730e-03 | 2.203 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 6.636795e-03 | 2.178 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 6.774146e-03 | 2.169 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 6.805356e-03 | 2.167 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.822826e-03 | 2.166 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 6.848598e-03 | 2.164 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 6.933474e-03 | 2.159 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 7.555153e-03 | 2.122 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 7.555153e-03 | 2.122 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 7.555153e-03 | 2.122 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 7.251237e-03 | 2.140 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 7.043360e-03 | 2.152 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 7.043360e-03 | 2.152 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 7.770025e-03 | 2.110 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 8.073584e-03 | 2.093 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 8.411812e-03 | 2.075 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 9.075697e-03 | 2.042 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 9.372514e-03 | 2.028 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 9.489078e-03 | 2.023 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.037330e-02 | 1.984 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 9.953877e-03 | 2.002 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 9.953877e-03 | 2.002 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 1.047004e-02 | 1.980 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.055666e-02 | 1.976 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.069962e-02 | 1.971 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.109147e-02 | 1.955 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.109147e-02 | 1.955 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.132338e-02 | 1.946 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 1.140253e-02 | 1.943 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.303987e-02 | 1.885 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.303987e-02 | 1.885 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.234241e-02 | 1.909 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.289621e-02 | 1.890 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.256602e-02 | 1.901 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.192013e-02 | 1.924 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.233564e-02 | 1.909 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.234467e-02 | 1.909 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.349878e-02 | 1.870 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.378382e-02 | 1.861 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.378499e-02 | 1.861 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.378499e-02 | 1.861 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.378499e-02 | 1.861 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 1.464032e-02 | 1.834 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.490464e-02 | 1.827 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.495236e-02 | 1.825 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.564835e-02 | 1.806 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.564835e-02 | 1.806 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.559991e-02 | 1.807 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.564835e-02 | 1.806 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 1.560852e-02 | 1.807 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 1.568008e-02 | 1.805 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 1.568008e-02 | 1.805 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.688230e-02 | 1.773 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.529132e-02 | 1.816 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.714902e-02 | 1.766 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.715980e-02 | 1.765 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 1.715980e-02 | 1.765 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.715980e-02 | 1.765 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.715980e-02 | 1.765 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.729743e-02 | 1.762 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.731496e-02 | 1.762 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.731496e-02 | 1.762 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.731496e-02 | 1.762 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.731496e-02 | 1.762 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.731496e-02 | 1.762 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.731496e-02 | 1.762 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 1.931789e-02 | 1.714 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.931789e-02 | 1.714 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.890233e-02 | 1.723 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.968074e-02 | 1.706 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.968074e-02 | 1.706 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 1.830244e-02 | 1.737 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.931789e-02 | 1.714 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.958310e-02 | 1.708 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.814615e-02 | 1.741 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.958310e-02 | 1.708 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.879003e-02 | 1.726 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 1.858287e-02 | 1.731 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.963855e-02 | 1.707 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.003753e-02 | 1.698 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 2.144415e-02 | 1.669 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 2.229372e-02 | 1.652 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 2.246538e-02 | 1.648 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.257912e-02 | 1.646 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 2.301835e-02 | 1.638 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 2.301835e-02 | 1.638 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 2.301835e-02 | 1.638 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.301835e-02 | 1.638 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 2.325343e-02 | 1.634 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.344564e-02 | 1.630 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 2.458998e-02 | 1.609 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 2.606587e-02 | 1.584 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 2.674086e-02 | 1.573 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.674086e-02 | 1.573 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 2.674086e-02 | 1.573 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 2.683711e-02 | 1.571 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 2.683711e-02 | 1.571 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.854938e-02 | 1.544 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.891671e-02 | 1.539 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 2.914276e-02 | 1.535 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.944418e-02 | 1.531 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 2.914276e-02 | 1.535 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.187459e-02 | 1.497 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.944418e-02 | 1.531 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 2.914276e-02 | 1.535 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 3.316992e-02 | 1.479 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 3.349366e-02 | 1.475 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 3.367963e-02 | 1.473 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 3.415656e-02 | 1.467 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 3.415656e-02 | 1.467 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 3.415656e-02 | 1.467 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 3.415656e-02 | 1.467 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.474845e-02 | 1.459 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 3.477487e-02 | 1.459 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 3.508311e-02 | 1.455 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.516112e-02 | 1.454 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 4.157700e-02 | 1.381 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 3.564666e-02 | 1.448 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.564666e-02 | 1.448 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.868817e-02 | 1.412 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 3.994017e-02 | 1.399 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 4.154058e-02 | 1.382 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.655186e-02 | 1.437 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 4.135745e-02 | 1.383 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 3.868817e-02 | 1.412 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 3.655186e-02 | 1.437 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.951152e-02 | 1.403 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 4.157700e-02 | 1.381 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 4.157700e-02 | 1.381 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 3.994017e-02 | 1.399 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 3.567292e-02 | 1.448 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 3.986005e-02 | 1.399 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 4.023049e-02 | 1.395 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 3.564666e-02 | 1.448 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 3.564666e-02 | 1.448 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 3.596818e-02 | 1.444 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 3.951152e-02 | 1.403 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 3.888625e-02 | 1.410 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 3.655186e-02 | 1.437 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 4.240744e-02 | 1.373 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 4.302079e-02 | 1.366 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 4.302079e-02 | 1.366 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.364644e-02 | 1.360 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 4.364644e-02 | 1.360 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 4.377651e-02 | 1.359 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 4.418716e-02 | 1.355 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 4.621205e-02 | 1.335 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 4.621205e-02 | 1.335 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 4.745300e-02 | 1.324 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 4.810338e-02 | 1.318 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.858530e-02 | 1.313 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 4.876723e-02 | 1.312 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 4.876723e-02 | 1.312 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.944935e-02 | 1.306 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 5.019312e-02 | 1.299 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 5.045375e-02 | 1.297 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 5.166017e-02 | 1.287 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 5.255526e-02 | 1.279 | 0 | 0 |
| RSK activation | R-HSA-444257 | 5.255526e-02 | 1.279 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 5.255526e-02 | 1.279 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 5.255526e-02 | 1.279 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 5.297795e-02 | 1.276 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 5.359599e-02 | 1.271 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 5.361389e-02 | 1.271 | 0 | 0 |
| Defective Base Excision Repair Associated with OGG1 | R-HSA-9656249 | 5.602822e-02 | 1.252 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 5.602822e-02 | 1.252 | 0 | 0 |
| Transport of glycerol from adipocytes to the liver by Aquaporins | R-HSA-432030 | 5.602822e-02 | 1.252 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 5.602822e-02 | 1.252 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 5.602822e-02 | 1.252 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 5.602822e-02 | 1.252 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 5.856653e-02 | 1.232 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 5.572661e-02 | 1.254 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 6.329884e-02 | 1.199 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 5.672012e-02 | 1.246 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 6.030881e-02 | 1.220 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 6.329884e-02 | 1.199 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 5.456759e-02 | 1.263 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 5.864059e-02 | 1.232 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 6.484605e-02 | 1.188 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 5.799741e-02 | 1.237 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 5.657981e-02 | 1.247 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 5.864059e-02 | 1.232 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 5.672012e-02 | 1.246 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 5.522871e-02 | 1.258 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 6.351520e-02 | 1.197 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 5.583481e-02 | 1.253 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 5.692829e-02 | 1.245 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 5.692829e-02 | 1.245 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 6.629754e-02 | 1.179 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 6.692818e-02 | 1.174 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 6.765830e-02 | 1.170 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 6.765830e-02 | 1.170 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 6.765830e-02 | 1.170 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 6.765830e-02 | 1.170 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 6.777659e-02 | 1.169 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 6.812524e-02 | 1.167 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 6.812524e-02 | 1.167 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 6.835310e-02 | 1.165 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.971397e-02 | 1.157 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 7.058293e-02 | 1.151 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.058293e-02 | 1.151 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 7.138060e-02 | 1.146 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 7.138060e-02 | 1.146 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 7.138060e-02 | 1.146 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 7.149351e-02 | 1.146 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 7.149351e-02 | 1.146 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 7.279440e-02 | 1.138 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 9.185654e-02 | 1.037 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 9.185654e-02 | 1.037 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 9.185654e-02 | 1.037 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 9.185654e-02 | 1.037 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 9.185654e-02 | 1.037 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 9.185654e-02 | 1.037 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 9.185654e-02 | 1.037 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 9.185654e-02 | 1.037 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 9.185654e-02 | 1.037 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 9.185654e-02 | 1.037 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 9.185654e-02 | 1.037 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 9.185654e-02 | 1.037 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 9.185654e-02 | 1.037 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 9.185654e-02 | 1.037 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 9.185654e-02 | 1.037 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 9.185654e-02 | 1.037 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 8.228858e-02 | 1.085 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 8.228858e-02 | 1.085 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 8.228858e-02 | 1.085 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 8.475268e-02 | 1.072 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 8.071372e-02 | 1.093 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 8.071372e-02 | 1.093 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 7.465474e-02 | 1.127 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 8.712777e-02 | 1.060 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 8.016635e-02 | 1.096 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 7.952880e-02 | 1.099 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 8.822736e-02 | 1.054 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 7.812742e-02 | 1.107 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 8.399232e-02 | 1.076 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 7.812742e-02 | 1.107 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 8.071372e-02 | 1.093 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 8.475268e-02 | 1.072 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 8.031636e-02 | 1.095 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 8.712777e-02 | 1.060 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 8.822736e-02 | 1.054 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 8.976928e-02 | 1.047 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 8.976928e-02 | 1.047 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 8.925707e-02 | 1.049 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 7.848656e-02 | 1.105 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.016635e-02 | 1.096 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 7.740676e-02 | 1.111 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 7.757634e-02 | 1.110 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 7.952880e-02 | 1.099 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.925707e-02 | 1.049 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 8.616261e-02 | 1.065 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 8.973739e-02 | 1.047 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.195728e-02 | 1.036 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 9.534516e-02 | 1.021 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 9.544402e-02 | 1.020 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 9.588878e-02 | 1.018 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 9.588878e-02 | 1.018 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 9.588878e-02 | 1.018 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 9.588878e-02 | 1.018 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 9.588878e-02 | 1.018 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 9.811494e-02 | 1.008 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 9.985024e-02 | 1.001 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 9.998184e-02 | 1.000 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.006687e-01 | 0.997 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 1.006687e-01 | 0.997 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 1.006687e-01 | 0.997 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 1.006687e-01 | 0.997 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 1.006687e-01 | 0.997 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 1.006687e-01 | 0.997 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.011983e-01 | 0.995 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.032902e-01 | 0.986 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.037323e-01 | 0.984 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.037323e-01 | 0.984 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.050505e-01 | 0.979 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 1.071720e-01 | 0.970 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 1.072732e-01 | 0.970 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.072732e-01 | 0.970 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.078216e-01 | 0.967 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.078216e-01 | 0.967 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 1.087452e-01 | 0.964 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.187182e-01 | 0.925 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.187182e-01 | 0.925 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.187182e-01 | 0.925 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.187182e-01 | 0.925 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.187182e-01 | 0.925 | 0 | 0 |
| Defective OGG1 Localization | R-HSA-9657050 | 1.187182e-01 | 0.925 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.187182e-01 | 0.925 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.187182e-01 | 0.925 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.187182e-01 | 0.925 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.187182e-01 | 0.925 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 1.187182e-01 | 0.925 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.187182e-01 | 0.925 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 1.187182e-01 | 0.925 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.187182e-01 | 0.925 | 0 | 0 |
| Defective OGG1 Substrate Binding | R-HSA-9656255 | 1.187182e-01 | 0.925 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.187182e-01 | 0.925 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 1.324839e-01 | 0.878 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 1.324839e-01 | 0.878 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 1.324839e-01 | 0.878 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 1.324839e-01 | 0.878 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.345687e-01 | 0.871 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.345687e-01 | 0.871 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 1.345687e-01 | 0.871 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 1.123991e-01 | 0.949 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 1.123991e-01 | 0.949 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.467763e-01 | 0.833 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 1.467763e-01 | 0.833 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 1.467763e-01 | 0.833 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 1.467763e-01 | 0.833 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 1.301740e-01 | 0.885 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.308212e-01 | 0.883 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.289551e-01 | 0.890 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 1.436047e-01 | 0.843 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 1.105534e-01 | 0.956 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 1.445363e-01 | 0.840 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.333389e-01 | 0.875 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 1.389163e-01 | 0.857 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 1.257651e-01 | 0.900 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 1.131964e-01 | 0.946 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.368582e-01 | 0.864 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.338003e-01 | 0.874 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 1.436047e-01 | 0.843 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.376262e-01 | 0.861 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.132966e-01 | 0.946 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.431386e-01 | 0.844 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 1.217560e-01 | 0.915 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.244603e-01 | 0.905 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 1.123991e-01 | 0.949 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.338891e-01 | 0.873 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.257651e-01 | 0.900 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 1.324839e-01 | 0.878 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 1.257651e-01 | 0.900 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.376095e-01 | 0.861 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.445363e-01 | 0.840 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.354458e-01 | 0.868 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 1.467763e-01 | 0.833 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 1.463274e-01 | 0.835 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.398789e-01 | 0.854 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 1.462818e-01 | 0.835 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.430533e-01 | 0.845 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.430533e-01 | 0.845 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 1.345687e-01 | 0.871 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 1.168453e-01 | 0.932 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.345687e-01 | 0.871 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 1.324839e-01 | 0.878 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 1.324839e-01 | 0.878 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.113636e-01 | 0.953 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.291226e-01 | 0.889 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.473025e-01 | 0.832 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.479571e-01 | 0.830 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.479571e-01 | 0.830 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 1.491289e-01 | 0.826 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.517200e-01 | 0.819 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 1.517817e-01 | 0.819 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.527253e-01 | 0.816 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.557641e-01 | 0.808 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.557641e-01 | 0.808 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.589697e-01 | 0.799 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 1.590095e-01 | 0.799 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 1.590095e-01 | 0.799 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 1.590095e-01 | 0.799 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 1.593419e-01 | 0.798 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.593419e-01 | 0.798 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.593419e-01 | 0.798 | 0 | 0 |
| Activation, translocation and oligomerization of BAX | R-HSA-114294 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective OGG1 Substrate Processing | R-HSA-9656256 | 2.233486e-01 | 0.651 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.233486e-01 | 0.651 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.233486e-01 | 0.651 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective SLC26A4 causes Pendred syndrome (PDS) | R-HSA-5619046 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective SLC2A10 causes arterial tortuosity syndrome (ATS) | R-HSA-5619068 | 2.233486e-01 | 0.651 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.233486e-01 | 0.651 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 2.233486e-01 | 0.651 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.233486e-01 | 0.651 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 1.762671e-01 | 0.754 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 1.762671e-01 | 0.754 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 1.762671e-01 | 0.754 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.762671e-01 | 0.754 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.762671e-01 | 0.754 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 1.762671e-01 | 0.754 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 1.762671e-01 | 0.754 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 1.762671e-01 | 0.754 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 1.762671e-01 | 0.754 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 1.762671e-01 | 0.754 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 2.218850e-01 | 0.654 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.218850e-01 | 0.654 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 2.218850e-01 | 0.654 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.218850e-01 | 0.654 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 2.218850e-01 | 0.654 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.640680e-01 | 0.785 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.640680e-01 | 0.785 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 1.640680e-01 | 0.785 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.952576e-01 | 0.709 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 1.705034e-01 | 0.768 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.705034e-01 | 0.768 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 2.277374e-01 | 0.643 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 2.277374e-01 | 0.643 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 2.277374e-01 | 0.643 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.214342e-01 | 0.655 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 1.829824e-01 | 0.738 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 1.829824e-01 | 0.738 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 2.120701e-01 | 0.674 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.751269e-01 | 0.757 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 2.019666e-01 | 0.695 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 2.347067e-01 | 0.629 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 2.347067e-01 | 0.629 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.925510e-01 | 0.715 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.327951e-01 | 0.633 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 2.326608e-01 | 0.633 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 2.326608e-01 | 0.633 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.309102e-01 | 0.637 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.935394e-01 | 0.713 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.849679e-01 | 0.733 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.019666e-01 | 0.695 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.019666e-01 | 0.695 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 1.782421e-01 | 0.749 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 1.901852e-01 | 0.721 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 2.272630e-01 | 0.643 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 2.321799e-01 | 0.634 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.016530e-01 | 0.695 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 2.347067e-01 | 0.629 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.019666e-01 | 0.695 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 1.870547e-01 | 0.728 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 2.121830e-01 | 0.673 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 1.659280e-01 | 0.780 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.925510e-01 | 0.715 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.216282e-01 | 0.654 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 2.216282e-01 | 0.654 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 1.901852e-01 | 0.721 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 1.762671e-01 | 0.754 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 2.418889e-01 | 0.616 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.272630e-01 | 0.643 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.952576e-01 | 0.709 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 1.870547e-01 | 0.728 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 1.731980e-01 | 0.761 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 1.901852e-01 | 0.721 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 1.647506e-01 | 0.783 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 2.292137e-01 | 0.640 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.640680e-01 | 0.785 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 2.064173e-01 | 0.685 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 1.705034e-01 | 0.768 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 1.691676e-01 | 0.772 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.218850e-01 | 0.654 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 2.321799e-01 | 0.634 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.949703e-01 | 0.710 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 2.116479e-01 | 0.674 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.821972e-01 | 0.739 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 1.705034e-01 | 0.768 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.093065e-01 | 0.679 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 2.218850e-01 | 0.654 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 2.214342e-01 | 0.655 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 2.046376e-01 | 0.689 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 2.019666e-01 | 0.695 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.272630e-01 | 0.643 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 2.347067e-01 | 0.629 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.818882e-01 | 0.740 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 1.821972e-01 | 0.739 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 1.821972e-01 | 0.739 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 2.278426e-01 | 0.642 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 2.052191e-01 | 0.688 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 2.233486e-01 | 0.651 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.233486e-01 | 0.651 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 1.762671e-01 | 0.754 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.218850e-01 | 0.654 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.218850e-01 | 0.654 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 1.640680e-01 | 0.785 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 1.952576e-01 | 0.709 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.705034e-01 | 0.768 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 1.705034e-01 | 0.768 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 1.954538e-01 | 0.709 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 1.838709e-01 | 0.735 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 2.242766e-01 | 0.649 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 2.277374e-01 | 0.643 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 2.242766e-01 | 0.649 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 2.242766e-01 | 0.649 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 2.019666e-01 | 0.695 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.640680e-01 | 0.785 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.954538e-01 | 0.709 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 2.272630e-01 | 0.643 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 2.321799e-01 | 0.634 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 2.277374e-01 | 0.643 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 1.946238e-01 | 0.711 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 2.277374e-01 | 0.643 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 2.418889e-01 | 0.616 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.430954e-01 | 0.614 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 2.218850e-01 | 0.654 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 2.218850e-01 | 0.654 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.640931e-01 | 0.785 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.901852e-01 | 0.721 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 2.214342e-01 | 0.655 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 2.457222e-01 | 0.610 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 2.467007e-01 | 0.608 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 2.475326e-01 | 0.606 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 2.475326e-01 | 0.606 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 2.480415e-01 | 0.605 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 2.482506e-01 | 0.605 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 2.482506e-01 | 0.605 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 2.482506e-01 | 0.605 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.482506e-01 | 0.605 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 2.482506e-01 | 0.605 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 2.482506e-01 | 0.605 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 2.482506e-01 | 0.605 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.482506e-01 | 0.605 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.499389e-01 | 0.602 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 2.554301e-01 | 0.593 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.565023e-01 | 0.591 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 2.579767e-01 | 0.588 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.579767e-01 | 0.588 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 2.579767e-01 | 0.588 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.579767e-01 | 0.588 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 2.588796e-01 | 0.587 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.610362e-01 | 0.583 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 2.611288e-01 | 0.583 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 2.611288e-01 | 0.583 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 2.611288e-01 | 0.583 | 0 | 0 |
| PI and PC transport between ER and Golgi membranes | R-HSA-1483196 | 3.155620e-01 | 0.501 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.155620e-01 | 0.501 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 3.155620e-01 | 0.501 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.155620e-01 | 0.501 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 3.155620e-01 | 0.501 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 3.155620e-01 | 0.501 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.155620e-01 | 0.501 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 3.155620e-01 | 0.501 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 3.155620e-01 | 0.501 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 3.155620e-01 | 0.501 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 3.155620e-01 | 0.501 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 3.155620e-01 | 0.501 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 3.155620e-01 | 0.501 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 3.155620e-01 | 0.501 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 3.155620e-01 | 0.501 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 3.155620e-01 | 0.501 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.155620e-01 | 0.501 | 0 | 0 |
| Defective SLC12A3 causes Gitelman syndrome (GS) | R-HSA-5619087 | 3.155620e-01 | 0.501 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 3.155620e-01 | 0.501 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 3.155620e-01 | 0.501 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.155620e-01 | 0.501 | 0 | 0 |
| MPS IIID - Sanfilippo syndrome D | R-HSA-2206305 | 3.155620e-01 | 0.501 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 3.155620e-01 | 0.501 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 3.155620e-01 | 0.501 | 0 | 0 |
| Intestinal infectious diseases | R-HSA-8942233 | 3.155620e-01 | 0.501 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 2.682857e-01 | 0.571 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 2.682857e-01 | 0.571 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 2.682857e-01 | 0.571 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 2.682857e-01 | 0.571 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 2.682857e-01 | 0.571 | 0 | 0 |
| TWIK related potassium channel (TREK) | R-HSA-1299503 | 3.968315e-01 | 0.401 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum) | R-HSA-5655799 | 3.968315e-01 | 0.401 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.968315e-01 | 0.401 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 3.968315e-01 | 0.401 | 0 | 0 |
| Defective visual phototransduction due to STRA6 loss of function | R-HSA-9918449 | 3.968315e-01 | 0.401 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 3.968315e-01 | 0.401 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 3.146407e-01 | 0.502 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 3.146407e-01 | 0.502 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 3.146407e-01 | 0.502 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 2.950813e-01 | 0.530 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 2.950813e-01 | 0.530 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 3.603072e-01 | 0.443 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 3.603072e-01 | 0.443 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 3.603072e-01 | 0.443 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 3.603072e-01 | 0.443 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 3.603072e-01 | 0.443 | 0 | 0 |
| The IPAF inflammasome | R-HSA-844623 | 4.684553e-01 | 0.329 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 4.684553e-01 | 0.329 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 4.684553e-01 | 0.329 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 4.684553e-01 | 0.329 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.684553e-01 | 0.329 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.684553e-01 | 0.329 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 4.684553e-01 | 0.329 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 3.292766e-01 | 0.482 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.292766e-01 | 0.482 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 3.036333e-01 | 0.518 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 4.047955e-01 | 0.393 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 4.047955e-01 | 0.393 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 4.047955e-01 | 0.393 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 4.047955e-01 | 0.393 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 3.634297e-01 | 0.440 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 3.318382e-01 | 0.479 | 0 | 0 |
| PKA activation | R-HSA-163615 | 3.318382e-01 | 0.479 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.059453e-01 | 0.514 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 3.059453e-01 | 0.514 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 2.646252e-01 | 0.577 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 3.304122e-01 | 0.481 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.304122e-01 | 0.481 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 4.477418e-01 | 0.349 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 4.477418e-01 | 0.349 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 4.477418e-01 | 0.349 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 4.477418e-01 | 0.349 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 3.272997e-01 | 0.485 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.272997e-01 | 0.485 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 4.306419e-01 | 0.366 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 3.797605e-01 | 0.420 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 3.146287e-01 | 0.502 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.867890e-01 | 0.542 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.714952e-01 | 0.430 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 4.165569e-01 | 0.380 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.888850e-01 | 0.311 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 4.888850e-01 | 0.311 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 4.888850e-01 | 0.311 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 3.636798e-01 | 0.439 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 2.880096e-01 | 0.541 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.936937e-01 | 0.405 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 4.443612e-01 | 0.352 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 4.443612e-01 | 0.352 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 4.289874e-01 | 0.368 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 2.664058e-01 | 0.574 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.246046e-01 | 0.372 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 4.717461e-01 | 0.326 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 4.951102e-01 | 0.305 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 4.951102e-01 | 0.305 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 4.598501e-01 | 0.337 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 4.773744e-01 | 0.321 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 4.773744e-01 | 0.321 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 4.773744e-01 | 0.321 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 3.586190e-01 | 0.445 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 4.012433e-01 | 0.397 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 4.012433e-01 | 0.397 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 5.010591e-01 | 0.300 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 3.874486e-01 | 0.412 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.536348e-01 | 0.343 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 4.566277e-01 | 0.340 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 5.248682e-01 | 0.280 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 5.248682e-01 | 0.280 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 5.248682e-01 | 0.280 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 3.243373e-01 | 0.489 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.533265e-01 | 0.344 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.773744e-01 | 0.321 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 2.827213e-01 | 0.549 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 2.682615e-01 | 0.571 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 3.318382e-01 | 0.479 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 4.306419e-01 | 0.366 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 3.190992e-01 | 0.496 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 3.036333e-01 | 0.518 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 4.724947e-01 | 0.326 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 2.757119e-01 | 0.560 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 2.838839e-01 | 0.547 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 4.477418e-01 | 0.349 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 3.493390e-01 | 0.457 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 3.939084e-01 | 0.405 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 4.246046e-01 | 0.372 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 4.316049e-01 | 0.365 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 4.824507e-01 | 0.317 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 3.055622e-01 | 0.515 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 4.477418e-01 | 0.349 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 3.035211e-01 | 0.518 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 2.941164e-01 | 0.531 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 3.493390e-01 | 0.457 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 4.951102e-01 | 0.305 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 4.047955e-01 | 0.393 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 3.550525e-01 | 0.450 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 3.797605e-01 | 0.420 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.888850e-01 | 0.311 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 5.243420e-01 | 0.280 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 3.318382e-01 | 0.479 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 4.951102e-01 | 0.305 | 0 | 0 |
| Formation of lateral plate mesoderm | R-HSA-9758920 | 2.682857e-01 | 0.571 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 3.603072e-01 | 0.443 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 3.972904e-01 | 0.401 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.477418e-01 | 0.349 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.493390e-01 | 0.457 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 4.306419e-01 | 0.366 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 4.165569e-01 | 0.380 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 3.457569e-01 | 0.461 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 5.029651e-01 | 0.298 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 3.208231e-01 | 0.494 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 2.993654e-01 | 0.524 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 3.318382e-01 | 0.479 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 3.376153e-01 | 0.472 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 3.376153e-01 | 0.472 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 3.146407e-01 | 0.502 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 2.757119e-01 | 0.560 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 4.047955e-01 | 0.393 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 4.477418e-01 | 0.349 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 4.165569e-01 | 0.380 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 3.590786e-01 | 0.445 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 2.817620e-01 | 0.550 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 4.307433e-01 | 0.366 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 3.797605e-01 | 0.420 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 4.618290e-01 | 0.336 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 5.239898e-01 | 0.281 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.243420e-01 | 0.280 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 3.530882e-01 | 0.452 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 4.056236e-01 | 0.392 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 2.975860e-01 | 0.526 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 2.975860e-01 | 0.526 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.625753e-01 | 0.581 | 0 | 0 |
| S Phase | R-HSA-69242 | 3.572908e-01 | 0.447 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 4.047955e-01 | 0.393 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 4.047955e-01 | 0.393 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 4.047955e-01 | 0.393 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 3.634297e-01 | 0.440 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 3.972904e-01 | 0.401 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.243373e-01 | 0.489 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 3.590786e-01 | 0.445 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 4.158635e-01 | 0.381 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 4.773744e-01 | 0.321 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 5.243160e-01 | 0.280 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 4.606059e-01 | 0.337 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 4.426928e-01 | 0.354 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 4.930670e-01 | 0.307 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 2.757119e-01 | 0.560 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.054549e-01 | 0.515 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 5.246974e-01 | 0.280 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 5.246974e-01 | 0.280 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 2.839118e-01 | 0.547 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 3.797605e-01 | 0.420 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.807818e-01 | 0.552 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 3.715604e-01 | 0.430 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 3.262325e-01 | 0.486 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 3.840201e-01 | 0.416 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 2.682857e-01 | 0.571 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 3.972904e-01 | 0.401 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 4.306419e-01 | 0.366 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.714952e-01 | 0.430 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 4.888850e-01 | 0.311 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 3.976633e-01 | 0.400 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 4.705089e-01 | 0.327 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 3.748069e-01 | 0.426 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 5.248682e-01 | 0.280 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 4.263797e-01 | 0.370 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 3.146407e-01 | 0.502 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 2.838839e-01 | 0.547 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 3.936937e-01 | 0.405 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 4.049563e-01 | 0.393 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 3.750661e-01 | 0.426 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 3.750661e-01 | 0.426 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 4.477418e-01 | 0.349 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 3.663592e-01 | 0.436 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 3.634297e-01 | 0.440 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 4.717461e-01 | 0.326 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 3.155620e-01 | 0.501 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 2.682857e-01 | 0.571 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 2.682857e-01 | 0.571 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 3.968315e-01 | 0.401 | 0 | 0 |
| Defective ABCC8 can cause hypo- and hyper-glycemias | R-HSA-5683177 | 3.968315e-01 | 0.401 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 3.968315e-01 | 0.401 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 3.968315e-01 | 0.401 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 3.603072e-01 | 0.443 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.603072e-01 | 0.443 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 3.603072e-01 | 0.443 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.684553e-01 | 0.329 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 4.047955e-01 | 0.393 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 4.047955e-01 | 0.393 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 3.035211e-01 | 0.518 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 4.306419e-01 | 0.366 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 3.155364e-01 | 0.501 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 3.756496e-01 | 0.425 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 3.748069e-01 | 0.426 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 4.815445e-01 | 0.317 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 5.248682e-01 | 0.280 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 4.165569e-01 | 0.380 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 3.007853e-01 | 0.522 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 3.272179e-01 | 0.485 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.089671e-01 | 0.388 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.089671e-01 | 0.388 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.132800e-01 | 0.290 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 3.618034e-01 | 0.442 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 3.272179e-01 | 0.485 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 5.224418e-01 | 0.282 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 3.384091e-01 | 0.471 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 3.618034e-01 | 0.442 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.418247e-01 | 0.355 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 4.477418e-01 | 0.349 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 4.148411e-01 | 0.382 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 4.618290e-01 | 0.336 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 4.254514e-01 | 0.371 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 3.837436e-01 | 0.416 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.241611e-01 | 0.281 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 4.047955e-01 | 0.393 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 2.838839e-01 | 0.547 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 4.044366e-01 | 0.393 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 4.289874e-01 | 0.368 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 4.459253e-01 | 0.351 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 4.404026e-01 | 0.356 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 3.146407e-01 | 0.502 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 3.146407e-01 | 0.502 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 3.603072e-01 | 0.443 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 3.036333e-01 | 0.518 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 3.059453e-01 | 0.514 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 4.477418e-01 | 0.349 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 3.884476e-01 | 0.411 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 3.055622e-01 | 0.515 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 5.132800e-01 | 0.290 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 3.884476e-01 | 0.411 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 4.888850e-01 | 0.311 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 3.226024e-01 | 0.491 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.304122e-01 | 0.481 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 4.769505e-01 | 0.322 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 4.747700e-01 | 0.324 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 3.292766e-01 | 0.482 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 4.747700e-01 | 0.324 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 3.272179e-01 | 0.485 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 5.125503e-01 | 0.290 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 3.603072e-01 | 0.443 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 3.634297e-01 | 0.440 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 3.318382e-01 | 0.479 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 4.632998e-01 | 0.334 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 4.533265e-01 | 0.344 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 4.717461e-01 | 0.326 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 4.951102e-01 | 0.305 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 4.488573e-01 | 0.348 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.071081e-01 | 0.295 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 4.228764e-01 | 0.374 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 3.054549e-01 | 0.515 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 5.010591e-01 | 0.300 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 3.376153e-01 | 0.472 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 3.146407e-01 | 0.502 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.684553e-01 | 0.329 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.319285e-01 | 0.365 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 4.986110e-01 | 0.302 | 0 | 0 |
| Diseases of Base Excision Repair | R-HSA-9605308 | 2.682857e-01 | 0.571 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 5.094080e-01 | 0.293 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 3.155620e-01 | 0.501 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 3.968315e-01 | 0.401 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 4.684553e-01 | 0.329 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 4.047955e-01 | 0.393 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 4.047955e-01 | 0.393 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 3.492755e-01 | 0.457 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 3.318382e-01 | 0.479 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 5.240619e-01 | 0.281 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 3.036333e-01 | 0.518 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.888850e-01 | 0.311 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 4.443612e-01 | 0.352 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.005049e-01 | 0.522 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 3.318382e-01 | 0.479 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 3.333883e-01 | 0.477 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.714952e-01 | 0.430 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 4.158635e-01 | 0.381 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 4.423158e-01 | 0.354 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 4.936833e-01 | 0.307 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 5.259476e-01 | 0.279 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 5.259476e-01 | 0.279 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 5.259476e-01 | 0.279 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 5.259476e-01 | 0.279 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 5.259476e-01 | 0.279 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 5.280480e-01 | 0.277 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 5.280480e-01 | 0.277 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 5.280480e-01 | 0.277 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.280480e-01 | 0.277 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 5.280480e-01 | 0.277 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 5.280480e-01 | 0.277 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 5.280480e-01 | 0.277 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 5.280480e-01 | 0.277 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 5.280480e-01 | 0.277 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 5.280480e-01 | 0.277 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 5.280480e-01 | 0.277 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 5.285343e-01 | 0.277 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 5.315777e-01 | 0.274 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.315777e-01 | 0.274 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 5.315777e-01 | 0.274 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 5.315777e-01 | 0.274 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 5.315777e-01 | 0.274 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 5.386275e-01 | 0.269 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 5.388174e-01 | 0.269 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 5.410095e-01 | 0.267 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 5.410095e-01 | 0.267 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 5.419251e-01 | 0.266 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 5.447895e-01 | 0.264 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 5.447895e-01 | 0.264 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 5.447895e-01 | 0.264 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.447895e-01 | 0.264 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 5.470878e-01 | 0.262 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 5.496926e-01 | 0.260 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 5.504430e-01 | 0.259 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 5.504430e-01 | 0.259 | 1 | 1 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 5.504430e-01 | 0.259 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 5.510639e-01 | 0.259 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 5.548259e-01 | 0.256 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 5.548259e-01 | 0.256 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 5.548259e-01 | 0.256 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 5.557122e-01 | 0.255 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 5.557122e-01 | 0.255 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 5.557122e-01 | 0.255 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 5.557122e-01 | 0.255 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 5.557122e-01 | 0.255 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 5.557122e-01 | 0.255 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 5.557122e-01 | 0.255 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 5.576288e-01 | 0.254 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 5.595437e-01 | 0.252 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 5.595437e-01 | 0.252 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 5.619658e-01 | 0.250 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 5.651209e-01 | 0.248 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 5.651209e-01 | 0.248 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 5.651209e-01 | 0.248 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 5.651209e-01 | 0.248 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 5.651209e-01 | 0.248 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 5.651209e-01 | 0.248 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 5.651209e-01 | 0.248 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 5.651209e-01 | 0.248 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.651209e-01 | 0.248 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 5.651209e-01 | 0.248 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 5.651209e-01 | 0.248 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 5.651209e-01 | 0.248 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 5.651209e-01 | 0.248 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 5.666154e-01 | 0.247 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 5.693243e-01 | 0.245 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 5.696806e-01 | 0.244 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 5.710706e-01 | 0.243 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 5.752726e-01 | 0.240 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 5.752726e-01 | 0.240 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 5.768654e-01 | 0.239 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 5.784673e-01 | 0.238 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 5.801484e-01 | 0.236 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 5.817302e-01 | 0.235 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 5.837982e-01 | 0.234 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 5.843277e-01 | 0.233 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 5.843277e-01 | 0.233 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 5.843277e-01 | 0.233 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 5.849788e-01 | 0.233 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 5.872074e-01 | 0.231 | 0 | 0 |
| Activation of AMPA receptors | R-HSA-399710 | 5.872074e-01 | 0.231 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.872074e-01 | 0.231 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.872074e-01 | 0.231 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 5.872074e-01 | 0.231 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 5.872074e-01 | 0.231 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 5.872074e-01 | 0.231 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.872074e-01 | 0.231 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 5.872074e-01 | 0.231 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 5.872074e-01 | 0.231 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.872074e-01 | 0.231 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.872074e-01 | 0.231 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 5.872074e-01 | 0.231 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.872074e-01 | 0.231 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 5.872074e-01 | 0.231 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 5.872074e-01 | 0.231 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.872074e-01 | 0.231 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 5.900913e-01 | 0.229 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 5.909822e-01 | 0.228 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 5.909822e-01 | 0.228 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 5.938663e-01 | 0.226 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 5.938663e-01 | 0.226 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 5.985111e-01 | 0.223 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 5.993058e-01 | 0.222 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 5.993058e-01 | 0.222 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 5.993058e-01 | 0.222 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 6.000477e-01 | 0.222 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 6.000477e-01 | 0.222 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 6.000477e-01 | 0.222 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 6.000477e-01 | 0.222 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 6.000477e-01 | 0.222 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 6.000477e-01 | 0.222 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 6.000477e-01 | 0.222 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 6.000477e-01 | 0.222 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 6.000477e-01 | 0.222 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 6.000477e-01 | 0.222 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 6.000477e-01 | 0.222 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 6.000477e-01 | 0.222 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 6.018274e-01 | 0.221 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 6.043727e-01 | 0.219 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 6.105252e-01 | 0.214 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.117386e-01 | 0.213 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 6.117386e-01 | 0.213 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 6.120251e-01 | 0.213 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 6.120251e-01 | 0.213 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 6.120251e-01 | 0.213 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 6.129436e-01 | 0.213 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 6.225018e-01 | 0.206 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 6.232616e-01 | 0.205 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 6.249691e-01 | 0.204 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 6.268229e-01 | 0.203 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 6.268229e-01 | 0.203 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 6.268229e-01 | 0.203 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 6.268229e-01 | 0.203 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 6.268229e-01 | 0.203 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.268840e-01 | 0.203 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 6.272306e-01 | 0.203 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 6.313459e-01 | 0.200 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 6.324228e-01 | 0.199 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 6.328154e-01 | 0.199 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 6.328154e-01 | 0.199 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 6.328154e-01 | 0.199 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 6.328154e-01 | 0.199 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 6.328154e-01 | 0.199 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 6.328154e-01 | 0.199 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 6.328154e-01 | 0.199 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 6.328154e-01 | 0.199 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 6.328154e-01 | 0.199 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 6.328154e-01 | 0.199 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 6.328154e-01 | 0.199 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 6.328154e-01 | 0.199 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 6.334036e-01 | 0.198 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 6.362334e-01 | 0.196 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.362334e-01 | 0.196 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.362334e-01 | 0.196 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.362334e-01 | 0.196 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.362334e-01 | 0.196 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.362334e-01 | 0.196 | 0 | 0 |
| Phase 1 - inactivation of fast Na+ channels | R-HSA-5576894 | 6.362334e-01 | 0.196 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 6.362334e-01 | 0.196 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 6.362334e-01 | 0.196 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 6.362334e-01 | 0.196 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 6.362334e-01 | 0.196 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 6.362334e-01 | 0.196 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 6.362334e-01 | 0.196 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 6.362334e-01 | 0.196 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 6.362334e-01 | 0.196 | 0 | 0 |
| Formation of the Editosome | R-HSA-75094 | 6.362334e-01 | 0.196 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 6.362334e-01 | 0.196 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 6.362334e-01 | 0.196 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 6.362334e-01 | 0.196 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 6.362334e-01 | 0.196 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 6.362334e-01 | 0.196 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 6.362334e-01 | 0.196 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 6.362334e-01 | 0.196 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 6.379081e-01 | 0.195 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 6.379081e-01 | 0.195 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 6.379081e-01 | 0.195 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 6.379081e-01 | 0.195 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 6.379081e-01 | 0.195 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 6.411733e-01 | 0.193 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 6.427426e-01 | 0.192 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 6.427426e-01 | 0.192 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 6.427426e-01 | 0.192 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 6.427426e-01 | 0.192 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 6.447607e-01 | 0.191 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 6.448298e-01 | 0.191 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 6.448298e-01 | 0.191 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.448298e-01 | 0.191 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 6.449316e-01 | 0.190 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 6.482300e-01 | 0.188 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 6.491646e-01 | 0.188 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 6.518807e-01 | 0.186 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 6.521511e-01 | 0.186 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 6.521511e-01 | 0.186 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 6.521511e-01 | 0.186 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 6.557379e-01 | 0.183 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 6.582699e-01 | 0.182 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 6.594365e-01 | 0.181 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 6.594365e-01 | 0.181 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 6.594365e-01 | 0.181 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 6.628152e-01 | 0.179 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 6.628152e-01 | 0.179 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 6.634440e-01 | 0.178 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 6.634440e-01 | 0.178 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 6.634440e-01 | 0.178 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 6.634440e-01 | 0.178 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 6.634440e-01 | 0.178 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 6.634440e-01 | 0.178 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 6.634440e-01 | 0.178 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 6.637153e-01 | 0.178 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 6.658755e-01 | 0.177 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 6.658755e-01 | 0.177 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 6.662681e-01 | 0.176 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 6.665341e-01 | 0.176 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 6.670987e-01 | 0.176 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 6.670987e-01 | 0.176 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 6.693159e-01 | 0.174 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 6.711917e-01 | 0.173 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 6.711917e-01 | 0.173 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 6.711917e-01 | 0.173 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 6.784834e-01 | 0.168 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 6.793797e-01 | 0.168 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 6.794393e-01 | 0.168 | 0 | 0 |
| Highly sodium permeable postsynaptic acetylcholine nicotinic receptors | R-HSA-629587 | 6.794393e-01 | 0.168 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.794393e-01 | 0.168 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 6.794393e-01 | 0.168 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 6.794393e-01 | 0.168 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.794393e-01 | 0.168 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 6.794393e-01 | 0.168 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 6.794393e-01 | 0.168 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 6.794393e-01 | 0.168 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 6.794393e-01 | 0.168 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 6.794393e-01 | 0.168 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 6.794393e-01 | 0.168 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 6.794393e-01 | 0.168 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 6.799986e-01 | 0.167 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 6.864533e-01 | 0.163 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 6.864533e-01 | 0.163 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 6.864533e-01 | 0.163 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 6.864533e-01 | 0.163 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 6.864533e-01 | 0.163 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 6.868029e-01 | 0.163 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 6.868029e-01 | 0.163 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 6.868029e-01 | 0.163 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 6.880995e-01 | 0.162 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.895313e-01 | 0.161 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 6.919795e-01 | 0.160 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 6.919795e-01 | 0.160 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 6.919795e-01 | 0.160 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 6.919795e-01 | 0.160 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.919795e-01 | 0.160 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 6.919795e-01 | 0.160 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 6.919795e-01 | 0.160 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 6.919795e-01 | 0.160 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 6.919795e-01 | 0.160 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 6.919795e-01 | 0.160 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 6.927325e-01 | 0.159 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 6.933661e-01 | 0.159 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 6.974846e-01 | 0.156 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 7.071322e-01 | 0.150 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 7.071322e-01 | 0.150 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 7.071613e-01 | 0.150 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 7.083670e-01 | 0.150 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 7.088274e-01 | 0.149 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 7.097000e-01 | 0.149 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 7.126116e-01 | 0.147 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 7.151362e-01 | 0.146 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 7.175157e-01 | 0.144 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 7.175157e-01 | 0.144 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 7.175157e-01 | 0.144 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 7.175157e-01 | 0.144 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 7.175157e-01 | 0.144 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 7.175157e-01 | 0.144 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 7.175157e-01 | 0.144 | 0 | 0 |
| mRNA Editing: C to U Conversion | R-HSA-72200 | 7.175157e-01 | 0.144 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 7.175157e-01 | 0.144 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 7.175157e-01 | 0.144 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.175157e-01 | 0.144 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 7.175157e-01 | 0.144 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 7.175157e-01 | 0.144 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 7.175157e-01 | 0.144 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 7.175157e-01 | 0.144 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 7.184868e-01 | 0.144 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 7.184868e-01 | 0.144 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 7.184868e-01 | 0.144 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 7.184868e-01 | 0.144 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 7.184868e-01 | 0.144 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 7.201303e-01 | 0.143 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 7.201303e-01 | 0.143 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 7.213360e-01 | 0.142 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 7.240778e-01 | 0.140 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 7.241664e-01 | 0.140 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 7.249713e-01 | 0.140 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 7.249713e-01 | 0.140 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 7.251434e-01 | 0.140 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 7.255722e-01 | 0.139 | 0 | 0 |
| Protein folding | R-HSA-391251 | 7.395738e-01 | 0.131 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 7.402808e-01 | 0.131 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 7.402808e-01 | 0.131 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 7.408474e-01 | 0.130 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 7.429550e-01 | 0.129 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.429550e-01 | 0.129 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 7.430452e-01 | 0.129 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 7.430452e-01 | 0.129 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 7.430452e-01 | 0.129 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 7.430452e-01 | 0.129 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 7.430452e-01 | 0.129 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 7.498535e-01 | 0.125 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 7.498535e-01 | 0.125 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 7.498535e-01 | 0.125 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 7.498535e-01 | 0.125 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 7.498535e-01 | 0.125 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.498535e-01 | 0.125 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 7.498535e-01 | 0.125 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.510713e-01 | 0.124 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 7.510713e-01 | 0.124 | 0 | 0 |
| Highly calcium permeable nicotinic acetylcholine receptors | R-HSA-629597 | 7.510713e-01 | 0.124 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 7.510713e-01 | 0.124 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 7.510713e-01 | 0.124 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 7.510713e-01 | 0.124 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 7.510713e-01 | 0.124 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 7.510713e-01 | 0.124 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 7.510713e-01 | 0.124 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 7.510713e-01 | 0.124 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 7.510713e-01 | 0.124 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 7.542231e-01 | 0.123 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 7.598739e-01 | 0.119 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 7.611908e-01 | 0.119 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 7.657434e-01 | 0.116 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 7.657434e-01 | 0.116 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 7.657434e-01 | 0.116 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 7.657434e-01 | 0.116 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 7.657434e-01 | 0.116 | 0 | 0 |
| Immune System | R-HSA-168256 | 7.662789e-01 | 0.116 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 7.665236e-01 | 0.115 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 7.672885e-01 | 0.115 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 7.679692e-01 | 0.115 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 7.682505e-01 | 0.114 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 7.685597e-01 | 0.114 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 7.685597e-01 | 0.114 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 7.685597e-01 | 0.114 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 7.778723e-01 | 0.109 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 7.794401e-01 | 0.108 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 7.806426e-01 | 0.108 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 7.806426e-01 | 0.108 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 7.806426e-01 | 0.108 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 7.806426e-01 | 0.108 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 7.806426e-01 | 0.108 | 0 | 0 |
| Degradation of GABA | R-HSA-916853 | 7.806426e-01 | 0.108 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 7.806426e-01 | 0.108 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 7.806426e-01 | 0.108 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 7.806426e-01 | 0.108 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 7.806426e-01 | 0.108 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 7.806426e-01 | 0.108 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 7.806426e-01 | 0.108 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 7.810030e-01 | 0.107 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 7.811351e-01 | 0.107 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 7.846423e-01 | 0.105 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 7.846603e-01 | 0.105 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 7.846603e-01 | 0.105 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 7.861077e-01 | 0.105 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 7.861077e-01 | 0.105 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 7.861077e-01 | 0.105 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 7.861077e-01 | 0.105 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 7.866769e-01 | 0.104 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 7.866769e-01 | 0.104 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 7.866769e-01 | 0.104 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 7.866769e-01 | 0.104 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 7.910980e-01 | 0.102 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 7.913110e-01 | 0.102 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 7.913276e-01 | 0.102 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 7.941069e-01 | 0.100 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 7.980755e-01 | 0.098 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 8.009976e-01 | 0.096 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.025378e-01 | 0.096 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 8.025378e-01 | 0.096 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 8.025378e-01 | 0.096 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 8.025378e-01 | 0.096 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 8.025378e-01 | 0.096 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 8.059446e-01 | 0.094 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 8.059446e-01 | 0.094 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 8.059446e-01 | 0.094 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 8.059446e-01 | 0.094 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 8.067025e-01 | 0.093 | 0 | 0 |
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | R-HSA-629594 | 8.067025e-01 | 0.093 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 8.067025e-01 | 0.093 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 8.067025e-01 | 0.093 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 8.067025e-01 | 0.093 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 8.067025e-01 | 0.093 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 8.067025e-01 | 0.093 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.067025e-01 | 0.093 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.067025e-01 | 0.093 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 8.067025e-01 | 0.093 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 8.067025e-01 | 0.093 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 8.067025e-01 | 0.093 | 0 | 0 |
| Sperm Motility And Taxes | R-HSA-1300642 | 8.067025e-01 | 0.093 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 8.067025e-01 | 0.093 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 8.067025e-01 | 0.093 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 8.067025e-01 | 0.093 | 0 | 0 |
| Serotonin receptors | R-HSA-390666 | 8.067025e-01 | 0.093 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 8.067025e-01 | 0.093 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 8.108237e-01 | 0.091 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 8.108237e-01 | 0.091 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 8.155936e-01 | 0.089 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 8.172212e-01 | 0.088 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 8.172314e-01 | 0.088 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 8.178937e-01 | 0.087 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 8.236466e-01 | 0.084 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 8.236466e-01 | 0.084 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 8.236466e-01 | 0.084 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 8.236466e-01 | 0.084 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 8.251648e-01 | 0.083 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 8.276522e-01 | 0.082 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 8.296679e-01 | 0.081 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 8.296679e-01 | 0.081 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 8.296679e-01 | 0.081 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 8.296679e-01 | 0.081 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.296679e-01 | 0.081 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 8.296679e-01 | 0.081 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 8.296679e-01 | 0.081 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 8.296679e-01 | 0.081 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 8.296679e-01 | 0.081 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 8.296679e-01 | 0.081 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 8.317262e-01 | 0.080 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.317262e-01 | 0.080 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 8.322215e-01 | 0.080 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 8.322215e-01 | 0.080 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.322215e-01 | 0.080 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 8.343852e-01 | 0.079 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 8.343852e-01 | 0.079 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 8.380327e-01 | 0.077 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 8.383364e-01 | 0.077 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 8.398830e-01 | 0.076 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 8.398830e-01 | 0.076 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 8.398830e-01 | 0.076 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 8.421892e-01 | 0.075 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 8.437171e-01 | 0.074 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 8.437171e-01 | 0.074 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 8.437171e-01 | 0.074 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 8.437171e-01 | 0.074 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 8.437171e-01 | 0.074 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 8.437171e-01 | 0.074 | 1 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.446383e-01 | 0.073 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 8.452352e-01 | 0.073 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.456251e-01 | 0.073 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 8.487895e-01 | 0.071 | 0 | 0 |
| Presynaptic nicotinic acetylcholine receptors | R-HSA-622323 | 8.499059e-01 | 0.071 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 8.499059e-01 | 0.071 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 8.499059e-01 | 0.071 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 8.499059e-01 | 0.071 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 8.499059e-01 | 0.071 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 8.499059e-01 | 0.071 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.499059e-01 | 0.071 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 8.499059e-01 | 0.071 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 8.547520e-01 | 0.068 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 8.547520e-01 | 0.068 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 8.547520e-01 | 0.068 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 8.651430e-01 | 0.063 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 8.651732e-01 | 0.063 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 8.651732e-01 | 0.063 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 8.655442e-01 | 0.063 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.655442e-01 | 0.063 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 8.655442e-01 | 0.063 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 8.668112e-01 | 0.062 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.677404e-01 | 0.062 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.677404e-01 | 0.062 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.677404e-01 | 0.062 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.677404e-01 | 0.062 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.677404e-01 | 0.062 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 8.677404e-01 | 0.062 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.677404e-01 | 0.062 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 8.677404e-01 | 0.062 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 8.677404e-01 | 0.062 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 8.677404e-01 | 0.062 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.677404e-01 | 0.062 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 8.677404e-01 | 0.062 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 8.677404e-01 | 0.062 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 8.679080e-01 | 0.062 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 8.683494e-01 | 0.061 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 8.683494e-01 | 0.061 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 8.683494e-01 | 0.061 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 8.683494e-01 | 0.061 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 8.683494e-01 | 0.061 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 8.743032e-01 | 0.058 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.743032e-01 | 0.058 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 8.754411e-01 | 0.058 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 8.772071e-01 | 0.057 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 8.786166e-01 | 0.056 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 8.802105e-01 | 0.055 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 8.807673e-01 | 0.055 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 8.807673e-01 | 0.055 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 8.807673e-01 | 0.055 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 8.829028e-01 | 0.054 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 8.829028e-01 | 0.054 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 8.829028e-01 | 0.054 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 8.834567e-01 | 0.054 | 0 | 0 |
| Acetylcholine binding and downstream events | R-HSA-181431 | 8.834567e-01 | 0.054 | 0 | 0 |
| Postsynaptic nicotinic acetylcholine receptors | R-HSA-622327 | 8.834567e-01 | 0.054 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 8.834567e-01 | 0.054 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 8.834567e-01 | 0.054 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 8.834567e-01 | 0.054 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 8.834567e-01 | 0.054 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.834567e-01 | 0.054 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.834567e-01 | 0.054 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 8.869479e-01 | 0.052 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 8.901187e-01 | 0.051 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 8.901187e-01 | 0.051 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 8.917230e-01 | 0.050 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.920939e-01 | 0.050 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 8.920939e-01 | 0.050 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 8.920939e-01 | 0.050 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 8.920939e-01 | 0.050 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 8.920939e-01 | 0.050 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 8.920939e-01 | 0.050 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 8.973062e-01 | 0.047 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 8.973062e-01 | 0.047 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 8.973062e-01 | 0.047 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 8.973062e-01 | 0.047 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 8.973062e-01 | 0.047 | 0 | 0 |
| Vitamin B2 (riboflavin) metabolism | R-HSA-196843 | 8.973062e-01 | 0.047 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 8.973062e-01 | 0.047 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.973062e-01 | 0.047 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 8.973062e-01 | 0.047 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 8.973062e-01 | 0.047 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.973062e-01 | 0.047 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 8.973062e-01 | 0.047 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.973062e-01 | 0.047 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.982861e-01 | 0.047 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 8.984008e-01 | 0.047 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 8.985982e-01 | 0.046 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 8.989505e-01 | 0.046 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 8.991638e-01 | 0.046 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 9.077581e-01 | 0.042 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.077581e-01 | 0.042 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 9.077581e-01 | 0.042 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 9.095106e-01 | 0.041 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.095106e-01 | 0.041 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 9.095106e-01 | 0.041 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 9.095106e-01 | 0.041 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 9.095106e-01 | 0.041 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 9.095106e-01 | 0.041 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 9.095106e-01 | 0.041 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 9.095106e-01 | 0.041 | 0 | 0 |
| Protein repair | R-HSA-5676934 | 9.095106e-01 | 0.041 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.095106e-01 | 0.041 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.095106e-01 | 0.041 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.109154e-01 | 0.041 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.118048e-01 | 0.040 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 9.138205e-01 | 0.039 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 9.168877e-01 | 0.038 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.187095e-01 | 0.037 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.202653e-01 | 0.036 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 9.202653e-01 | 0.036 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 9.202653e-01 | 0.036 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 9.202653e-01 | 0.036 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 9.202653e-01 | 0.036 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 9.202653e-01 | 0.036 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 9.202653e-01 | 0.036 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 9.202653e-01 | 0.036 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 9.202653e-01 | 0.036 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 9.202653e-01 | 0.036 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 9.202653e-01 | 0.036 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 9.202653e-01 | 0.036 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.202653e-01 | 0.036 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 9.202653e-01 | 0.036 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.203431e-01 | 0.036 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.203431e-01 | 0.036 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.203431e-01 | 0.036 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.203431e-01 | 0.036 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.245840e-01 | 0.034 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.251793e-01 | 0.034 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.254672e-01 | 0.034 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 9.267043e-01 | 0.033 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 9.277916e-01 | 0.033 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.280983e-01 | 0.032 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 9.280983e-01 | 0.032 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.291898e-01 | 0.032 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 9.297423e-01 | 0.032 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 9.297423e-01 | 0.032 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 9.297423e-01 | 0.032 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 9.297423e-01 | 0.032 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 9.297423e-01 | 0.032 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 9.297423e-01 | 0.032 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 9.297423e-01 | 0.032 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.297423e-01 | 0.032 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.297423e-01 | 0.032 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 9.297423e-01 | 0.032 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 9.297423e-01 | 0.032 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.306256e-01 | 0.031 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 9.327553e-01 | 0.030 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 9.327553e-01 | 0.030 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 9.351360e-01 | 0.029 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.351360e-01 | 0.029 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.355474e-01 | 0.029 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 9.355474e-01 | 0.029 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 9.355474e-01 | 0.029 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 9.357611e-01 | 0.029 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.380934e-01 | 0.028 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 9.380934e-01 | 0.028 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 9.380934e-01 | 0.028 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.380934e-01 | 0.028 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 9.380934e-01 | 0.028 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.380934e-01 | 0.028 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 9.400066e-01 | 0.027 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.411686e-01 | 0.026 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.411686e-01 | 0.026 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 9.415170e-01 | 0.026 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.415170e-01 | 0.026 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.415170e-01 | 0.026 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 9.430861e-01 | 0.025 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.442982e-01 | 0.025 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.450089e-01 | 0.025 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 9.454523e-01 | 0.024 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 9.454523e-01 | 0.024 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.454523e-01 | 0.024 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.454523e-01 | 0.024 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.454523e-01 | 0.024 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.454523e-01 | 0.024 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 9.458794e-01 | 0.024 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.463323e-01 | 0.024 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.463323e-01 | 0.024 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.463323e-01 | 0.024 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 9.463323e-01 | 0.024 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.472981e-01 | 0.024 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 9.472981e-01 | 0.024 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.472981e-01 | 0.024 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 9.487897e-01 | 0.023 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.503850e-01 | 0.022 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.510718e-01 | 0.022 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 9.519368e-01 | 0.021 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.519368e-01 | 0.021 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.519368e-01 | 0.021 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.519368e-01 | 0.021 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.519368e-01 | 0.021 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.519368e-01 | 0.021 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 9.519368e-01 | 0.021 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.519368e-01 | 0.021 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 9.529134e-01 | 0.021 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.554181e-01 | 0.020 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.554181e-01 | 0.020 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.566582e-01 | 0.019 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 9.572660e-01 | 0.019 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.576507e-01 | 0.019 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 9.576507e-01 | 0.019 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 9.576507e-01 | 0.019 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 9.576507e-01 | 0.019 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 9.576507e-01 | 0.019 | 0 | 0 |
| Keratan sulfate degradation | R-HSA-2022857 | 9.576507e-01 | 0.019 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.576507e-01 | 0.019 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.576507e-01 | 0.019 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.576507e-01 | 0.019 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.594009e-01 | 0.018 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 9.603428e-01 | 0.018 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.615460e-01 | 0.017 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 9.626271e-01 | 0.017 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 9.626857e-01 | 0.017 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 9.626857e-01 | 0.017 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 9.626857e-01 | 0.017 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.626857e-01 | 0.017 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 9.626857e-01 | 0.017 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.627213e-01 | 0.016 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.630477e-01 | 0.016 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.630477e-01 | 0.016 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 9.630477e-01 | 0.016 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.634924e-01 | 0.016 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 9.637917e-01 | 0.016 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.645137e-01 | 0.016 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.654127e-01 | 0.015 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.654127e-01 | 0.015 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.654127e-01 | 0.015 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.654127e-01 | 0.015 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 9.654127e-01 | 0.015 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 9.654127e-01 | 0.015 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.661186e-01 | 0.015 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 9.671223e-01 | 0.015 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.671223e-01 | 0.015 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.671223e-01 | 0.015 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.671223e-01 | 0.015 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.682187e-01 | 0.014 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 9.689038e-01 | 0.014 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 9.693380e-01 | 0.014 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.694353e-01 | 0.013 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.694353e-01 | 0.013 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.699865e-01 | 0.013 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.699865e-01 | 0.013 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 9.710316e-01 | 0.013 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.710316e-01 | 0.013 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.710316e-01 | 0.013 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 9.710316e-01 | 0.013 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.710316e-01 | 0.013 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.710316e-01 | 0.013 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.710316e-01 | 0.013 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.710316e-01 | 0.013 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.710316e-01 | 0.013 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.720102e-01 | 0.012 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.720102e-01 | 0.012 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.720540e-01 | 0.012 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 9.720540e-01 | 0.012 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.720540e-01 | 0.012 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.725860e-01 | 0.012 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.727486e-01 | 0.012 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.743774e-01 | 0.011 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.743774e-01 | 0.011 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.744763e-01 | 0.011 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.744763e-01 | 0.011 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.744763e-01 | 0.011 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.744763e-01 | 0.011 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.744763e-01 | 0.011 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.744763e-01 | 0.011 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 9.744763e-01 | 0.011 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.748949e-01 | 0.011 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.748949e-01 | 0.011 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.771531e-01 | 0.010 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.773552e-01 | 0.010 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.773552e-01 | 0.010 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.773552e-01 | 0.010 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.774556e-01 | 0.010 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.774556e-01 | 0.010 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 9.775116e-01 | 0.010 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.775116e-01 | 0.010 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.775116e-01 | 0.010 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.783378e-01 | 0.010 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 9.785590e-01 | 0.009 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.787333e-01 | 0.009 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 9.792091e-01 | 0.009 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.796425e-01 | 0.009 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.796508e-01 | 0.009 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.797625e-01 | 0.009 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.797625e-01 | 0.009 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.797625e-01 | 0.009 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.797625e-01 | 0.009 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.797625e-01 | 0.009 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.801860e-01 | 0.009 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.801860e-01 | 0.009 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 9.801860e-01 | 0.009 | 0 | 0 |
| Fertilization | R-HSA-1187000 | 9.801860e-01 | 0.009 | 0 | 0 |
| Retinoid cycle disease events | R-HSA-2453864 | 9.801860e-01 | 0.009 | 0 | 0 |
| Diseases associated with visual transduction | R-HSA-2474795 | 9.801860e-01 | 0.009 | 0 | 0 |
| Diseases of the neuronal system | R-HSA-9675143 | 9.801860e-01 | 0.009 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.801860e-01 | 0.009 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.811397e-01 | 0.008 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.820909e-01 | 0.008 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.825426e-01 | 0.008 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.825426e-01 | 0.008 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.825426e-01 | 0.008 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.828983e-01 | 0.007 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.828983e-01 | 0.007 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.837093e-01 | 0.007 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.837093e-01 | 0.007 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.837093e-01 | 0.007 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.841582e-01 | 0.007 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 9.846190e-01 | 0.007 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 9.846190e-01 | 0.007 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.846190e-01 | 0.007 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.846190e-01 | 0.007 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.846190e-01 | 0.007 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.854980e-01 | 0.006 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 9.859560e-01 | 0.006 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.863731e-01 | 0.006 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 9.864485e-01 | 0.006 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.864485e-01 | 0.006 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 9.864485e-01 | 0.006 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.864485e-01 | 0.006 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 9.869035e-01 | 0.006 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 9.880605e-01 | 0.005 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.880605e-01 | 0.005 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 9.880605e-01 | 0.005 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 9.880605e-01 | 0.005 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 9.880605e-01 | 0.005 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.884851e-01 | 0.005 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.884851e-01 | 0.005 | 0 | 0 |
| Mucopolysaccharidoses | R-HSA-2206281 | 9.894808e-01 | 0.005 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 9.898035e-01 | 0.004 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.904998e-01 | 0.004 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.905727e-01 | 0.004 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.905813e-01 | 0.004 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.905813e-01 | 0.004 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 9.907323e-01 | 0.004 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 9.907323e-01 | 0.004 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.907323e-01 | 0.004 | 0 | 0 |
| Synthesis of glycosylphosphatidylinositol (GPI) | R-HSA-162710 | 9.907323e-01 | 0.004 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 9.914277e-01 | 0.004 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.914745e-01 | 0.004 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 9.915662e-01 | 0.004 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 9.915662e-01 | 0.004 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.918349e-01 | 0.004 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.918527e-01 | 0.004 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.923469e-01 | 0.003 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 9.924502e-01 | 0.003 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.925533e-01 | 0.003 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.925533e-01 | 0.003 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.926317e-01 | 0.003 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.928064e-01 | 0.003 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.928064e-01 | 0.003 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.928064e-01 | 0.003 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.930227e-01 | 0.003 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 9.930348e-01 | 0.003 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.932432e-01 | 0.003 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.936624e-01 | 0.003 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.936624e-01 | 0.003 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.936624e-01 | 0.003 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.936624e-01 | 0.003 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 9.936624e-01 | 0.003 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.936921e-01 | 0.003 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.944165e-01 | 0.002 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 9.944165e-01 | 0.002 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.945804e-01 | 0.002 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.945922e-01 | 0.002 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.946109e-01 | 0.002 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.946232e-01 | 0.002 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.946568e-01 | 0.002 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.946568e-01 | 0.002 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.946829e-01 | 0.002 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.947941e-01 | 0.002 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.950810e-01 | 0.002 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.950810e-01 | 0.002 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.951638e-01 | 0.002 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.953688e-01 | 0.002 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 9.956562e-01 | 0.002 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.956664e-01 | 0.002 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.956664e-01 | 0.002 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 9.956760e-01 | 0.002 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.956760e-01 | 0.002 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.958212e-01 | 0.002 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.961348e-01 | 0.002 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.961821e-01 | 0.002 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.961821e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.961821e-01 | 0.002 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.961821e-01 | 0.002 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.961821e-01 | 0.002 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.965457e-01 | 0.002 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.966366e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.968047e-01 | 0.001 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.970369e-01 | 0.001 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.970369e-01 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.972378e-01 | 0.001 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.973896e-01 | 0.001 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.973896e-01 | 0.001 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.973896e-01 | 0.001 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.974821e-01 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.975111e-01 | 0.001 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 9.977645e-01 | 0.001 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.979741e-01 | 0.001 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.979741e-01 | 0.001 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.979741e-01 | 0.001 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.980368e-01 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.981820e-01 | 0.001 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.982263e-01 | 0.001 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.984278e-01 | 0.001 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.984278e-01 | 0.001 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.985637e-01 | 0.001 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.986044e-01 | 0.001 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.986150e-01 | 0.001 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.986150e-01 | 0.001 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.986150e-01 | 0.001 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.986150e-01 | 0.001 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.986150e-01 | 0.001 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.986750e-01 | 0.001 | 0 | 0 |
| The canonical retinoid cycle in rods (twilight vision) | R-HSA-2453902 | 9.987800e-01 | 0.001 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.987800e-01 | 0.001 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.988242e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.988828e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.989203e-01 | 0.000 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.989252e-01 | 0.000 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.989253e-01 | 0.000 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.989279e-01 | 0.000 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.990532e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.990532e-01 | 0.000 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.991660e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.991853e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.992125e-01 | 0.000 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.992653e-01 | 0.000 | 0 | 0 |
| Keratan sulfate/keratin metabolism | R-HSA-1638074 | 9.992653e-01 | 0.000 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.992653e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.993244e-01 | 0.000 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.993528e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.994299e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.994424e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.994514e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.995032e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.995032e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.995032e-01 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 9.996325e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.996977e-01 | 0.000 | 0 | 0 |
| Digestion | R-HSA-8935690 | 9.996977e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.997793e-01 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 9.997934e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.997934e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.998091e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.998180e-01 | 0.000 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.998180e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.998397e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.998397e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.998513e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.998626e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.998697e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.998756e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.998756e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.998897e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.998905e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.998905e-01 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 9.999035e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.999085e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.999252e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.999314e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.999341e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999365e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999489e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999518e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.999529e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.999550e-01 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.999585e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.999603e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999651e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999699e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999709e-01 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.999729e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999763e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.999792e-01 | 0.000 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.999807e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.999815e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999837e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999874e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999874e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999899e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999914e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.999928e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999936e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999941e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999952e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999954e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999965e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999969e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999977e-01 | 0.000 | 1 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999991e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999993e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999994e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999999e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999999e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999999e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.999999e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 1 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle, Mitotic | R-HSA-69278 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.776357e-15 | 14.750 | 0 | 0 |
| M Phase | R-HSA-68886 | 9.214851e-15 | 14.036 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.832978e-12 | 11.737 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.573719e-12 | 11.589 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.609490e-11 | 10.793 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 6.272005e-11 | 10.203 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 7.419443e-11 | 10.130 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.277858e-10 | 9.894 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.630826e-10 | 9.580 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 6.833540e-10 | 9.165 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 8.670406e-10 | 9.062 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 9.028920e-10 | 9.044 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 9.314726e-10 | 9.031 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.363524e-09 | 8.865 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 2.336235e-09 | 8.631 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 2.745917e-09 | 8.561 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 3.911713e-09 | 8.408 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 8.009041e-09 | 8.096 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.359960e-08 | 7.866 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.673055e-08 | 7.776 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 2.052029e-08 | 7.688 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 2.870766e-08 | 7.542 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 3.169178e-08 | 7.499 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 4.263710e-08 | 7.370 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 6.502116e-08 | 7.187 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 6.502116e-08 | 7.187 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 7.322821e-08 | 7.135 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 7.333551e-08 | 7.135 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 7.333551e-08 | 7.135 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 6.934196e-08 | 7.159 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 8.625494e-08 | 7.064 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.268380e-07 | 6.897 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.471748e-07 | 6.832 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.823431e-07 | 6.739 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.822024e-07 | 6.739 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.875096e-07 | 6.727 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.995035e-07 | 6.700 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 2.204493e-07 | 6.657 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 2.346853e-07 | 6.630 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 2.414360e-07 | 6.617 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 2.476124e-07 | 6.606 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 3.022455e-07 | 6.520 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 2.981998e-07 | 6.525 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 3.107344e-07 | 6.508 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 3.914179e-07 | 6.407 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.328288e-07 | 6.364 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 4.624170e-07 | 6.335 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 5.688622e-07 | 6.245 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 6.898184e-07 | 6.161 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 7.293067e-07 | 6.137 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 7.808115e-07 | 6.107 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 9.653972e-07 | 6.015 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.283221e-06 | 5.892 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 1.287559e-06 | 5.890 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.338216e-06 | 5.873 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.460105e-06 | 5.836 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.473905e-06 | 5.832 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.567265e-06 | 5.805 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.580220e-06 | 5.801 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.664416e-06 | 5.779 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 1.812113e-06 | 5.742 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 2.052144e-06 | 5.688 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 2.080508e-06 | 5.682 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 2.239637e-06 | 5.650 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 2.522440e-06 | 5.598 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.603393e-06 | 5.584 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 2.746614e-06 | 5.561 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 2.834511e-06 | 5.548 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 3.086939e-06 | 5.510 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 3.356959e-06 | 5.474 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 3.558428e-06 | 5.449 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 4.111225e-06 | 5.386 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 4.147547e-06 | 5.382 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.534211e-06 | 5.343 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 4.534211e-06 | 5.343 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.712391e-06 | 5.327 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 4.965445e-06 | 5.304 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 4.989768e-06 | 5.302 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 5.081977e-06 | 5.294 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 5.324644e-06 | 5.274 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 5.559269e-06 | 5.255 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 6.033299e-06 | 5.219 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 6.705307e-06 | 5.174 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 6.926330e-06 | 5.159 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 7.226413e-06 | 5.141 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 8.402932e-06 | 5.076 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 9.349946e-06 | 5.029 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 9.349946e-06 | 5.029 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 9.383816e-06 | 5.028 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 1.090166e-05 | 4.963 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.037129e-05 | 4.984 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 1.130957e-05 | 4.947 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.251430e-05 | 4.903 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.301230e-05 | 4.886 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 1.327763e-05 | 4.877 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.465053e-05 | 4.834 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.548075e-05 | 4.810 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.550048e-05 | 4.810 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.635652e-05 | 4.786 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 1.692339e-05 | 4.772 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 1.722719e-05 | 4.764 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 2.113754e-05 | 4.675 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.191579e-05 | 4.659 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 2.258915e-05 | 4.646 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 2.464452e-05 | 4.608 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.499986e-05 | 4.602 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.659621e-05 | 4.575 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 2.669409e-05 | 4.574 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 2.722538e-05 | 4.565 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 2.742643e-05 | 4.562 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 2.889598e-05 | 4.539 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 2.889598e-05 | 4.539 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 3.312814e-05 | 4.480 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.279705e-05 | 4.484 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 3.314890e-05 | 4.480 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 3.314890e-05 | 4.480 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 3.599024e-05 | 4.444 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 4.286036e-05 | 4.368 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 4.811549e-05 | 4.318 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.784885e-05 | 4.320 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 4.525852e-05 | 4.344 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 5.100849e-05 | 4.292 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 5.541386e-05 | 4.256 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 5.505579e-05 | 4.259 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 5.277644e-05 | 4.278 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 5.277644e-05 | 4.278 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 5.443860e-05 | 4.264 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 5.381340e-05 | 4.269 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 5.766277e-05 | 4.239 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 6.743631e-05 | 4.171 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 7.162233e-05 | 4.145 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 7.494784e-05 | 4.125 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 7.678060e-05 | 4.115 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 7.925211e-05 | 4.101 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 8.565975e-05 | 4.067 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 9.492575e-05 | 4.023 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.074334e-04 | 3.969 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.108163e-04 | 3.955 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.153192e-04 | 3.938 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 1.240893e-04 | 3.906 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 1.373070e-04 | 3.862 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.509246e-04 | 3.821 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.513527e-04 | 3.820 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.823066e-04 | 3.739 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.826619e-04 | 3.738 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.823066e-04 | 3.739 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.772678e-04 | 3.751 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.758829e-04 | 3.755 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.898479e-04 | 3.722 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.986503e-04 | 3.702 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 2.018605e-04 | 3.695 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 2.021942e-04 | 3.694 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 2.165715e-04 | 3.664 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.243101e-04 | 3.649 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.277689e-04 | 3.643 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 2.786601e-04 | 3.555 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 2.817906e-04 | 3.550 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.853300e-04 | 3.545 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 2.905802e-04 | 3.537 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.225253e-04 | 3.491 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 3.195439e-04 | 3.495 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.005347e-04 | 3.522 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.294710e-04 | 3.482 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.311401e-04 | 3.480 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 3.315775e-04 | 3.479 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 3.385413e-04 | 3.470 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 3.414155e-04 | 3.467 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 3.414155e-04 | 3.467 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.471459e-04 | 3.459 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 3.498219e-04 | 3.456 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 3.528974e-04 | 3.452 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 3.830141e-04 | 3.417 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 3.832905e-04 | 3.416 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 3.879058e-04 | 3.411 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 3.879058e-04 | 3.411 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 4.050059e-04 | 3.393 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 4.209943e-04 | 3.376 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 4.915131e-04 | 3.308 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 5.167778e-04 | 3.287 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 5.293021e-04 | 3.276 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 5.602021e-04 | 3.252 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 5.902587e-04 | 3.229 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 5.964304e-04 | 3.224 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 6.019400e-04 | 3.220 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 6.212225e-04 | 3.207 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 6.212225e-04 | 3.207 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 6.268292e-04 | 3.203 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 6.268292e-04 | 3.203 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 6.463385e-04 | 3.190 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 6.616658e-04 | 3.179 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 6.856226e-04 | 3.164 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 6.948265e-04 | 3.158 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 6.955580e-04 | 3.158 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 6.989799e-04 | 3.156 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 7.617463e-04 | 3.118 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 8.836053e-04 | 3.054 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 8.594742e-04 | 3.066 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 8.858150e-04 | 3.053 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 8.917859e-04 | 3.050 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 9.254153e-04 | 3.034 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 9.282217e-04 | 3.032 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 9.341297e-04 | 3.030 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 9.417826e-04 | 3.026 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 9.417826e-04 | 3.026 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.055020e-03 | 2.977 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 1.083410e-03 | 2.965 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.143707e-03 | 2.942 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.250266e-03 | 2.903 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.266208e-03 | 2.897 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.344243e-03 | 2.872 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 1.353998e-03 | 2.868 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 1.353998e-03 | 2.868 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.364208e-03 | 2.865 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.451587e-03 | 2.838 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.470893e-03 | 2.832 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 1.654911e-03 | 2.781 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.677386e-03 | 2.775 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.699279e-03 | 2.770 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.739064e-03 | 2.760 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.646256e-03 | 2.784 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.782391e-03 | 2.749 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.905890e-03 | 2.720 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 1.931057e-03 | 2.714 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.931872e-03 | 2.714 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 1.961559e-03 | 2.707 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.990803e-03 | 2.701 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 2.189210e-03 | 2.660 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 2.289763e-03 | 2.640 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 2.453977e-03 | 2.610 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.573310e-03 | 2.590 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 2.573310e-03 | 2.590 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 2.614401e-03 | 2.583 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.614401e-03 | 2.583 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 2.727486e-03 | 2.564 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 2.759024e-03 | 2.559 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 2.788361e-03 | 2.555 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 2.957834e-03 | 2.529 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 2.957834e-03 | 2.529 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 2.957834e-03 | 2.529 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.104870e-03 | 2.508 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 3.107050e-03 | 2.508 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 3.174719e-03 | 2.498 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 3.174719e-03 | 2.498 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 3.174719e-03 | 2.498 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 3.565931e-03 | 2.448 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 3.331397e-03 | 2.477 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.542415e-03 | 2.451 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.827664e-03 | 2.417 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 3.384191e-03 | 2.471 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 3.542415e-03 | 2.451 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 3.844780e-03 | 2.415 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.999579e-03 | 2.398 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.125090e-03 | 2.385 | 0 | 0 |
| Depurination | R-HSA-73927 | 4.216720e-03 | 2.375 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.310298e-03 | 2.365 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.310298e-03 | 2.365 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 4.335991e-03 | 2.363 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 4.335991e-03 | 2.363 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 4.502144e-03 | 2.347 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 4.705728e-03 | 2.327 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 4.748839e-03 | 2.323 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 4.806376e-03 | 2.318 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 4.843214e-03 | 2.315 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 4.990209e-03 | 2.302 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 5.066376e-03 | 2.295 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 5.159679e-03 | 2.287 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 5.227060e-03 | 2.282 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 5.736968e-03 | 2.241 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.753593e-03 | 2.240 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 5.872765e-03 | 2.231 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 5.872765e-03 | 2.231 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 6.043628e-03 | 2.219 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 6.131779e-03 | 2.212 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 6.443655e-03 | 2.191 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 6.443655e-03 | 2.191 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 6.531103e-03 | 2.185 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 6.565572e-03 | 2.183 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 6.565572e-03 | 2.183 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 6.734544e-03 | 2.172 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 6.799635e-03 | 2.168 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 6.799635e-03 | 2.168 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 6.799635e-03 | 2.168 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 6.799635e-03 | 2.168 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 6.874654e-03 | 2.163 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 6.874654e-03 | 2.163 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 6.884555e-03 | 2.162 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 6.884555e-03 | 2.162 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 7.308463e-03 | 2.136 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 8.446592e-03 | 2.073 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 7.329115e-03 | 2.135 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 7.821371e-03 | 2.107 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 7.821371e-03 | 2.107 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.297766e-03 | 2.137 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 7.277756e-03 | 2.138 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 7.308463e-03 | 2.136 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 7.821371e-03 | 2.107 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 8.649007e-03 | 2.063 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 8.799959e-03 | 2.056 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 9.056747e-03 | 2.043 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 9.131507e-03 | 2.039 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 9.279107e-03 | 2.032 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 9.398110e-03 | 2.027 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 9.649504e-03 | 2.015 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 9.649504e-03 | 2.015 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 9.649504e-03 | 2.015 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 9.649504e-03 | 2.015 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 9.649504e-03 | 2.015 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 9.649504e-03 | 2.015 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 9.649504e-03 | 2.015 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 9.649504e-03 | 2.015 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 9.649504e-03 | 2.015 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 9.649504e-03 | 2.015 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 9.649504e-03 | 2.015 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 9.690382e-03 | 2.014 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 9.831231e-03 | 2.007 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 9.927777e-03 | 2.003 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.035561e-02 | 1.985 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.077664e-02 | 1.968 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.095216e-02 | 1.961 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.098216e-02 | 1.959 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 1.098216e-02 | 1.959 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.112129e-02 | 1.954 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.134643e-02 | 1.945 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.145227e-02 | 1.941 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.159318e-02 | 1.936 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.177609e-02 | 1.929 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 1.177609e-02 | 1.929 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.257360e-02 | 1.901 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.288592e-02 | 1.890 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 1.288592e-02 | 1.890 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.344274e-02 | 1.872 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.358869e-02 | 1.867 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.412944e-02 | 1.850 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.416576e-02 | 1.849 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.417471e-02 | 1.848 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.434487e-02 | 1.843 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.464186e-02 | 1.834 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.502747e-02 | 1.823 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.521435e-02 | 1.818 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.708910e-02 | 1.767 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 1.753699e-02 | 1.756 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.753699e-02 | 1.756 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.773121e-02 | 1.751 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 1.814726e-02 | 1.741 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.680473e-02 | 1.775 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.742333e-02 | 1.759 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.775607e-02 | 1.751 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.884031e-02 | 1.725 | 0 | 0 |
| Translation | R-HSA-72766 | 1.699657e-02 | 1.770 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.743474e-02 | 1.759 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.825331e-02 | 1.739 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 1.680473e-02 | 1.775 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.708910e-02 | 1.767 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 1.816708e-02 | 1.741 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 1.816708e-02 | 1.741 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.980197e-02 | 1.703 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 1.869695e-02 | 1.728 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.003919e-02 | 1.698 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.870793e-02 | 1.728 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 2.008522e-02 | 1.697 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.008972e-02 | 1.697 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 2.046207e-02 | 1.689 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.050120e-02 | 1.688 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 2.050120e-02 | 1.688 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 2.066408e-02 | 1.685 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 2.082348e-02 | 1.681 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.090053e-02 | 1.680 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.183367e-02 | 1.661 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 2.391016e-02 | 1.621 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 2.397789e-02 | 1.620 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 2.397789e-02 | 1.620 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 2.441629e-02 | 1.612 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 2.441629e-02 | 1.612 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 2.460101e-02 | 1.609 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 2.467284e-02 | 1.608 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.587844e-02 | 1.587 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 2.670893e-02 | 1.573 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.685216e-02 | 1.571 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.757662e-02 | 1.559 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.757662e-02 | 1.559 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.766492e-02 | 1.558 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 2.766492e-02 | 1.558 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.784461e-02 | 1.555 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 2.784461e-02 | 1.555 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 2.784461e-02 | 1.555 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 2.784461e-02 | 1.555 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 2.784461e-02 | 1.555 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 2.784461e-02 | 1.555 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.784461e-02 | 1.555 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.863034e-02 | 1.543 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.863034e-02 | 1.543 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.863034e-02 | 1.543 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.885941e-02 | 1.540 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.885941e-02 | 1.540 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.885941e-02 | 1.540 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.980358e-02 | 1.526 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.986690e-02 | 1.525 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.060721e-02 | 1.514 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 3.070975e-02 | 1.513 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 3.095465e-02 | 1.509 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.095465e-02 | 1.509 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 3.104928e-02 | 1.508 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 3.221833e-02 | 1.492 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 3.264488e-02 | 1.486 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 3.267106e-02 | 1.486 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 3.267106e-02 | 1.486 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 3.270038e-02 | 1.485 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.506051e-02 | 1.455 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 3.577405e-02 | 1.446 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 3.577405e-02 | 1.446 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.613890e-02 | 1.442 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 3.677126e-02 | 1.434 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 3.708207e-02 | 1.431 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 3.800928e-02 | 1.420 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 3.849484e-02 | 1.415 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 3.909570e-02 | 1.408 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 3.983331e-02 | 1.400 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 4.091391e-02 | 1.388 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 4.218282e-02 | 1.375 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 4.218282e-02 | 1.375 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 5.354602e-02 | 1.271 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 4.765713e-02 | 1.322 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 4.986113e-02 | 1.302 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 5.192794e-02 | 1.285 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 4.370219e-02 | 1.359 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 4.809083e-02 | 1.318 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 4.986109e-02 | 1.302 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 4.811138e-02 | 1.318 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 5.322200e-02 | 1.274 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 5.322200e-02 | 1.274 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 5.192794e-02 | 1.285 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.105155e-02 | 1.292 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.105155e-02 | 1.292 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 4.234927e-02 | 1.373 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 4.091391e-02 | 1.388 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.765713e-02 | 1.322 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 4.218282e-02 | 1.375 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 5.322200e-02 | 1.274 | 1 | 1 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 5.069446e-02 | 1.295 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 5.069446e-02 | 1.295 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 4.027081e-02 | 1.395 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 4.904321e-02 | 1.309 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 4.621793e-02 | 1.335 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 5.290198e-02 | 1.277 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 4.344301e-02 | 1.362 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 4.734694e-02 | 1.325 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 4.708843e-02 | 1.327 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 4.487551e-02 | 1.348 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 4.368922e-02 | 1.360 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 4.336299e-02 | 1.363 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.766143e-02 | 1.322 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.766143e-02 | 1.322 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 4.621793e-02 | 1.335 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 4.621793e-02 | 1.335 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 4.698285e-02 | 1.328 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 4.027081e-02 | 1.395 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 5.420642e-02 | 1.266 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 5.420642e-02 | 1.266 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.444766e-02 | 1.264 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.556901e-02 | 1.255 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 5.582773e-02 | 1.253 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 5.599035e-02 | 1.252 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 5.633984e-02 | 1.249 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 5.642676e-02 | 1.249 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.653878e-02 | 1.248 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 5.653878e-02 | 1.248 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 5.653878e-02 | 1.248 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 5.667433e-02 | 1.247 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 5.667433e-02 | 1.247 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 5.667433e-02 | 1.247 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 5.708895e-02 | 1.243 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 5.861883e-02 | 1.232 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 5.861883e-02 | 1.232 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 5.861883e-02 | 1.232 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 6.085619e-02 | 1.216 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 6.351667e-02 | 1.197 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 6.351667e-02 | 1.197 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 6.351667e-02 | 1.197 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 6.411782e-02 | 1.193 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 6.411782e-02 | 1.193 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 6.411782e-02 | 1.193 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.463446e-02 | 1.190 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 6.472404e-02 | 1.189 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 6.472404e-02 | 1.189 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 6.472404e-02 | 1.189 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 6.479086e-02 | 1.188 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 6.479086e-02 | 1.188 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 6.479086e-02 | 1.188 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 6.479086e-02 | 1.188 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 6.575961e-02 | 1.182 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 6.640106e-02 | 1.178 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 6.660112e-02 | 1.177 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 6.732889e-02 | 1.172 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 6.732889e-02 | 1.172 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 6.912697e-02 | 1.160 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 6.979470e-02 | 1.156 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 6.988616e-02 | 1.156 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 6.988616e-02 | 1.156 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 6.988616e-02 | 1.156 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 6.998485e-02 | 1.155 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 6.998485e-02 | 1.155 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 7.014022e-02 | 1.154 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 7.014022e-02 | 1.154 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 7.113661e-02 | 1.148 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 7.122270e-02 | 1.147 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 7.166378e-02 | 1.145 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.357379e-02 | 1.133 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 7.433602e-02 | 1.129 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 7.433602e-02 | 1.129 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 7.454803e-02 | 1.128 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 7.456191e-02 | 1.127 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 7.456191e-02 | 1.127 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 7.651323e-02 | 1.116 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 7.901676e-02 | 1.102 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 7.901676e-02 | 1.102 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 7.901676e-02 | 1.102 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 7.914895e-02 | 1.102 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 7.928951e-02 | 1.101 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.974039e-02 | 1.098 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 8.076118e-02 | 1.093 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 8.330493e-02 | 1.079 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 8.416577e-02 | 1.075 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 8.509414e-02 | 1.070 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 8.675000e-02 | 1.062 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 8.688261e-02 | 1.061 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 8.709125e-02 | 1.060 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 8.758329e-02 | 1.058 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 8.758329e-02 | 1.058 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.020340e-01 | 0.991 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.020340e-01 | 0.991 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.020340e-01 | 0.991 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 1.020340e-01 | 0.991 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.020340e-01 | 0.991 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.020340e-01 | 0.991 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.020340e-01 | 0.991 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.020340e-01 | 0.991 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.020340e-01 | 0.991 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.020340e-01 | 0.991 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.020340e-01 | 0.991 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.020340e-01 | 0.991 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.020340e-01 | 0.991 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.020340e-01 | 0.991 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 1.020340e-01 | 0.991 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.020340e-01 | 0.991 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.020340e-01 | 0.991 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.020340e-01 | 0.991 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.020340e-01 | 0.991 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.020340e-01 | 0.991 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 1.019473e-01 | 0.992 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 1.019473e-01 | 0.992 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 1.019473e-01 | 0.992 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.019473e-01 | 0.992 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.019473e-01 | 0.992 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 9.478056e-02 | 1.023 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 9.478056e-02 | 1.023 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.169626e-01 | 0.932 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.169626e-01 | 0.932 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.169626e-01 | 0.932 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 1.133989e-01 | 0.945 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.133989e-01 | 0.945 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.133989e-01 | 0.945 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.133989e-01 | 0.945 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 9.171657e-02 | 1.038 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 9.171657e-02 | 1.038 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.316143e-01 | 0.881 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.316143e-01 | 0.881 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.053969e-01 | 0.977 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 1.200174e-01 | 0.921 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 9.776098e-02 | 1.010 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.213228e-01 | 0.916 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.213228e-01 | 0.916 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.719163e-02 | 1.012 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 1.185713e-01 | 0.926 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 9.032013e-02 | 1.044 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.275609e-01 | 0.894 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.275609e-01 | 0.894 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.085017e-01 | 0.965 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 9.776098e-02 | 1.010 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.199661e-01 | 0.921 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.275609e-01 | 0.894 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 1.199661e-01 | 0.921 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 1.169626e-01 | 0.932 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 1.233867e-01 | 0.909 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 8.797542e-02 | 1.056 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.233867e-01 | 0.909 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 8.797542e-02 | 1.056 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 1.039599e-01 | 0.983 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 9.639838e-02 | 1.016 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 9.641782e-02 | 1.016 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 9.641782e-02 | 1.016 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 1.085598e-01 | 0.964 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 1.259072e-01 | 0.900 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.136434e-01 | 0.944 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.136434e-01 | 0.944 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.114946e-01 | 0.953 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 1.213228e-01 | 0.916 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 9.310767e-02 | 1.031 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.169626e-01 | 0.932 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.133989e-01 | 0.945 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.310063e-01 | 0.883 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.200174e-01 | 0.921 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 1.096900e-01 | 0.960 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 1.200174e-01 | 0.921 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 1.040716e-01 | 0.983 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 9.478056e-02 | 1.023 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 1.053969e-01 | 0.977 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 9.548995e-02 | 1.020 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.169626e-01 | 0.932 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 1.279535e-01 | 0.893 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 9.776098e-02 | 1.010 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 9.719163e-02 | 1.012 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 1.319628e-01 | 0.880 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 1.319628e-01 | 0.880 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 1.319628e-01 | 0.880 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 1.335634e-01 | 0.874 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 1.335634e-01 | 0.874 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.348531e-01 | 0.870 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 1.355297e-01 | 0.868 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.355297e-01 | 0.868 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 1.355297e-01 | 0.868 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.371508e-01 | 0.863 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 1.371508e-01 | 0.863 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 1.371508e-01 | 0.863 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 1.371508e-01 | 0.863 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 1.371508e-01 | 0.863 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.371508e-01 | 0.863 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.389437e-01 | 0.857 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 1.392093e-01 | 0.856 | 1 | 0 |
| Leishmania infection | R-HSA-9658195 | 1.401240e-01 | 0.853 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 1.401240e-01 | 0.853 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 1.408594e-01 | 0.851 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.408594e-01 | 0.851 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.408594e-01 | 0.851 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 1.408594e-01 | 0.851 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 1.408594e-01 | 0.851 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.408594e-01 | 0.851 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 1.408594e-01 | 0.851 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.433551e-01 | 0.844 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.441631e-01 | 0.841 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 1.445292e-01 | 0.840 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 1.445292e-01 | 0.840 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 1.490600e-01 | 0.827 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 1.490600e-01 | 0.827 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.509410e-01 | 0.821 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.509410e-01 | 0.821 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 1.509410e-01 | 0.821 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.509410e-01 | 0.821 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.509410e-01 | 0.821 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.509410e-01 | 0.821 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.509410e-01 | 0.821 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 1.509421e-01 | 0.821 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 1.509421e-01 | 0.821 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.509421e-01 | 0.821 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.509801e-01 | 0.821 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.517608e-01 | 0.819 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.518789e-01 | 0.819 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 1.936624e-01 | 0.713 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 1.936624e-01 | 0.713 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.936624e-01 | 0.713 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.936624e-01 | 0.713 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.936624e-01 | 0.713 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.936624e-01 | 0.713 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 1.936624e-01 | 0.713 | 0 | 0 |
| Hereditary fructose intolerance | R-HSA-5657560 | 1.936624e-01 | 0.713 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 1.936624e-01 | 0.713 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 1.936624e-01 | 0.713 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 1.936624e-01 | 0.713 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 1.936624e-01 | 0.713 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH3 | R-HSA-5632927 | 1.936624e-01 | 0.713 | 0 | 0 |
| Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) | R-HSA-5619043 | 1.936624e-01 | 0.713 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.936624e-01 | 0.713 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 2.759459e-01 | 0.559 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective HK1 causes hexokinase deficiency (HK deficiency) | R-HSA-5619056 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 2.759459e-01 | 0.559 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 2.759459e-01 | 0.559 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 2.759459e-01 | 0.559 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 2.759459e-01 | 0.559 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 2.759459e-01 | 0.559 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.759459e-01 | 0.559 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.759459e-01 | 0.559 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.759459e-01 | 0.559 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.759459e-01 | 0.559 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 1.745227e-01 | 0.758 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.745227e-01 | 0.758 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 1.745227e-01 | 0.758 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 1.745227e-01 | 0.758 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 1.745227e-01 | 0.758 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 2.132545e-01 | 0.671 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 2.132545e-01 | 0.671 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 2.132545e-01 | 0.671 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.132545e-01 | 0.671 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 2.132545e-01 | 0.671 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 2.132545e-01 | 0.671 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 2.132545e-01 | 0.671 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 1.662155e-01 | 0.779 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.662155e-01 | 0.779 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 2.526800e-01 | 0.597 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 2.526800e-01 | 0.597 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 2.526800e-01 | 0.597 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 2.526800e-01 | 0.597 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 2.526800e-01 | 0.597 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.927768e-01 | 0.715 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.927768e-01 | 0.715 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.927768e-01 | 0.715 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.927768e-01 | 0.715 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.927768e-01 | 0.715 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.712674e-01 | 0.766 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 1.712674e-01 | 0.766 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.712674e-01 | 0.766 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.712674e-01 | 0.766 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 2.202957e-01 | 0.657 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 2.202957e-01 | 0.657 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 2.202957e-01 | 0.657 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.922550e-01 | 0.534 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 2.922550e-01 | 0.534 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 2.922550e-01 | 0.534 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 2.922550e-01 | 0.534 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 2.922550e-01 | 0.534 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.922550e-01 | 0.534 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 2.485361e-01 | 0.605 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 2.485361e-01 | 0.605 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 2.485361e-01 | 0.605 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 2.485361e-01 | 0.605 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.485361e-01 | 0.605 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.485361e-01 | 0.605 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.485361e-01 | 0.605 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.485361e-01 | 0.605 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 2.485361e-01 | 0.605 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 2.485361e-01 | 0.605 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.485361e-01 | 0.605 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.485361e-01 | 0.605 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.485361e-01 | 0.605 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.485361e-01 | 0.605 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.690041e-01 | 0.772 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 1.690041e-01 | 0.772 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.144502e-01 | 0.669 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 1.868402e-01 | 0.729 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.868402e-01 | 0.729 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 2.772760e-01 | 0.557 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 2.772760e-01 | 0.557 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.370674e-01 | 0.625 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 2.370674e-01 | 0.625 | 0 | 0 |
| PKA activation | R-HSA-163615 | 2.370674e-01 | 0.625 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 2.370674e-01 | 0.625 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 2.370674e-01 | 0.625 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.793532e-01 | 0.746 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 1.793532e-01 | 0.746 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.793532e-01 | 0.746 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.576418e-01 | 0.802 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.243682e-01 | 0.649 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 2.602094e-01 | 0.585 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 2.602094e-01 | 0.585 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 2.439164e-01 | 0.613 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.837598e-01 | 0.547 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 2.837598e-01 | 0.547 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 2.837598e-01 | 0.547 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 2.837598e-01 | 0.547 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 2.837598e-01 | 0.547 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 1.578846e-01 | 0.802 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 1.796832e-01 | 0.745 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 2.842162e-01 | 0.546 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 2.027801e-01 | 0.693 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 2.027801e-01 | 0.693 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 2.027801e-01 | 0.693 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 2.027801e-01 | 0.693 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 2.027801e-01 | 0.693 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 2.952246e-01 | 0.530 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.587195e-01 | 0.799 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 2.638901e-01 | 0.579 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.003926e-01 | 0.698 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.924769e-01 | 0.716 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 1.665813e-01 | 0.778 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.953559e-01 | 0.709 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 2.149937e-01 | 0.668 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 2.837598e-01 | 0.547 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.869320e-01 | 0.728 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.578846e-01 | 0.802 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.461605e-01 | 0.609 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 1.745227e-01 | 0.758 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 2.243682e-01 | 0.649 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 2.602094e-01 | 0.585 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 2.202957e-01 | 0.657 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 1.924769e-01 | 0.716 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 2.526800e-01 | 0.597 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.853982e-01 | 0.732 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 1.631341e-01 | 0.787 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.853982e-01 | 0.732 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 2.544622e-01 | 0.594 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 2.544622e-01 | 0.594 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 2.544622e-01 | 0.594 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 3.048227e-01 | 0.516 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.922550e-01 | 0.534 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 2.144502e-01 | 0.669 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 1.551737e-01 | 0.809 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 2.631933e-01 | 0.580 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.943048e-01 | 0.712 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.576418e-01 | 0.802 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 1.745227e-01 | 0.758 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 2.202957e-01 | 0.657 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 2.370674e-01 | 0.625 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.288456e-01 | 0.640 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 1.576418e-01 | 0.802 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 2.908606e-01 | 0.536 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.650566e-01 | 0.782 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.322081e-01 | 0.634 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 2.485361e-01 | 0.605 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 2.302306e-01 | 0.638 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.576418e-01 | 0.802 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 2.164651e-01 | 0.665 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 2.132545e-01 | 0.671 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 1.712744e-01 | 0.766 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 1.712744e-01 | 0.766 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.908167e-01 | 0.719 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 2.786110e-01 | 0.555 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 2.952246e-01 | 0.530 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 2.207665e-01 | 0.656 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 1.906503e-01 | 0.720 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.868402e-01 | 0.729 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 2.132545e-01 | 0.671 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 1.910764e-01 | 0.719 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 1.950280e-01 | 0.710 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 2.439164e-01 | 0.613 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 3.052111e-01 | 0.515 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 2.638901e-01 | 0.579 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 1.950280e-01 | 0.710 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 2.202998e-01 | 0.657 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.602094e-01 | 0.585 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 1.888149e-01 | 0.724 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 2.638901e-01 | 0.579 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 2.160727e-01 | 0.665 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 1.793532e-01 | 0.746 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 2.202998e-01 | 0.657 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 2.653894e-01 | 0.576 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 1.868402e-01 | 0.729 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.081972e-01 | 0.682 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 2.147788e-01 | 0.668 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.853166e-01 | 0.732 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 1.936624e-01 | 0.713 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 1.936624e-01 | 0.713 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 2.759459e-01 | 0.559 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 2.759459e-01 | 0.559 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 2.759459e-01 | 0.559 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 2.202957e-01 | 0.657 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 2.202957e-01 | 0.657 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 2.202957e-01 | 0.657 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 2.485361e-01 | 0.605 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 1.639068e-01 | 0.785 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 1.639068e-01 | 0.785 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 2.370674e-01 | 0.625 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.712744e-01 | 0.766 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.243682e-01 | 0.649 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 1.853982e-01 | 0.732 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 1.999822e-01 | 0.699 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 1.999822e-01 | 0.699 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 1.905247e-01 | 0.720 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 2.160727e-01 | 0.665 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 2.461605e-01 | 0.609 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 2.461605e-01 | 0.609 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 2.952246e-01 | 0.530 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.605106e-01 | 0.794 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 2.281846e-01 | 0.642 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 2.160727e-01 | 0.665 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 2.033613e-01 | 0.692 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 2.370674e-01 | 0.625 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 2.160727e-01 | 0.665 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 2.160727e-01 | 0.665 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 2.473291e-01 | 0.607 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 2.242124e-01 | 0.649 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 2.160727e-01 | 0.665 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.002563e-01 | 0.698 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 2.303983e-01 | 0.638 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 2.034949e-01 | 0.691 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 2.147788e-01 | 0.668 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 2.461605e-01 | 0.609 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 2.034949e-01 | 0.691 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 2.034949e-01 | 0.691 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 2.424130e-01 | 0.615 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 1.927768e-01 | 0.715 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.144502e-01 | 0.669 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 1.576418e-01 | 0.802 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 1.576418e-01 | 0.802 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 2.027801e-01 | 0.693 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 2.786110e-01 | 0.555 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 2.786110e-01 | 0.555 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 2.376777e-01 | 0.624 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.906503e-01 | 0.720 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 2.560998e-01 | 0.592 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 2.118693e-01 | 0.674 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 1.587211e-01 | 0.799 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 2.523796e-01 | 0.598 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 2.771575e-01 | 0.557 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 2.364466e-01 | 0.626 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 2.772760e-01 | 0.557 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.053186e-01 | 0.688 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 2.759459e-01 | 0.559 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 2.759459e-01 | 0.559 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 2.288456e-01 | 0.640 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 2.622438e-01 | 0.581 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.950280e-01 | 0.710 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.606823e-01 | 0.584 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 3.048227e-01 | 0.516 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.868402e-01 | 0.729 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 2.922550e-01 | 0.534 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 2.748880e-01 | 0.561 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.089654e-01 | 0.680 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 1.868402e-01 | 0.729 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 2.144502e-01 | 0.669 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 1.745227e-01 | 0.758 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.132545e-01 | 0.671 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 2.922550e-01 | 0.534 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 1.927768e-01 | 0.715 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 2.560998e-01 | 0.592 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 1.924769e-01 | 0.716 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 2.560998e-01 | 0.592 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.578846e-01 | 0.802 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 1.910764e-01 | 0.719 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 3.055850e-01 | 0.515 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 3.055850e-01 | 0.515 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 3.063093e-01 | 0.514 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 3.063093e-01 | 0.514 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 3.076062e-01 | 0.512 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 3.076062e-01 | 0.512 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 3.076062e-01 | 0.512 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 3.081296e-01 | 0.511 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.120470e-01 | 0.506 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 3.193077e-01 | 0.496 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 3.244342e-01 | 0.489 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 3.256389e-01 | 0.487 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 3.256389e-01 | 0.487 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 3.256389e-01 | 0.487 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 3.256389e-01 | 0.487 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 3.276952e-01 | 0.485 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.290406e-01 | 0.483 | 0 | 0 |
| RSK activation | R-HSA-444257 | 3.315386e-01 | 0.479 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 3.315386e-01 | 0.479 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 3.315386e-01 | 0.479 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 3.315386e-01 | 0.479 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 3.315386e-01 | 0.479 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.315386e-01 | 0.479 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.316409e-01 | 0.479 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 3.331596e-01 | 0.477 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 3.354478e-01 | 0.474 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 3.354478e-01 | 0.474 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.354478e-01 | 0.474 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 3.354478e-01 | 0.474 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 3.354478e-01 | 0.474 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 3.354478e-01 | 0.474 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 3.375959e-01 | 0.472 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 3.376353e-01 | 0.472 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 3.461702e-01 | 0.461 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 3.465961e-01 | 0.460 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 3.465961e-01 | 0.460 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 3.472277e-01 | 0.459 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 3.498371e-01 | 0.456 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 3.498371e-01 | 0.456 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 3.498371e-01 | 0.456 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum) | R-HSA-5655799 | 3.498371e-01 | 0.456 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 3.498371e-01 | 0.456 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 3.498371e-01 | 0.456 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 3.498371e-01 | 0.456 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 3.498371e-01 | 0.456 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 3.498371e-01 | 0.456 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 3.498371e-01 | 0.456 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 3.498371e-01 | 0.456 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 3.517088e-01 | 0.454 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 3.557619e-01 | 0.449 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 3.557619e-01 | 0.449 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 3.557619e-01 | 0.449 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 3.557619e-01 | 0.449 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 3.557619e-01 | 0.449 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 3.564554e-01 | 0.448 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 3.573680e-01 | 0.447 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 3.611718e-01 | 0.442 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 3.645208e-01 | 0.438 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 3.645208e-01 | 0.438 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 3.645208e-01 | 0.438 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 3.645208e-01 | 0.438 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 3.645208e-01 | 0.438 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 3.645208e-01 | 0.438 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 3.645208e-01 | 0.438 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 3.645208e-01 | 0.438 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 3.676285e-01 | 0.435 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 3.684857e-01 | 0.434 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.701784e-01 | 0.432 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 3.701784e-01 | 0.432 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 3.701784e-01 | 0.432 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.701784e-01 | 0.432 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 3.701784e-01 | 0.432 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.701784e-01 | 0.432 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.701784e-01 | 0.432 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 3.751285e-01 | 0.426 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 3.752927e-01 | 0.426 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 3.753429e-01 | 0.426 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 3.794189e-01 | 0.421 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.798735e-01 | 0.420 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 3.806801e-01 | 0.419 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 3.931444e-01 | 0.405 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 3.933760e-01 | 0.405 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 3.933760e-01 | 0.405 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 3.933760e-01 | 0.405 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 3.933760e-01 | 0.405 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 3.933760e-01 | 0.405 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 3.933760e-01 | 0.405 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 3.933760e-01 | 0.405 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 3.933760e-01 | 0.405 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 3.933760e-01 | 0.405 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.946512e-01 | 0.404 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 4.038865e-01 | 0.394 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 4.078970e-01 | 0.389 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 4.078970e-01 | 0.389 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 4.078970e-01 | 0.389 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.078970e-01 | 0.389 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 4.078970e-01 | 0.389 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.078970e-01 | 0.389 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 4.078970e-01 | 0.389 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 4.078970e-01 | 0.389 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 4.078970e-01 | 0.389 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 4.078970e-01 | 0.389 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 4.078970e-01 | 0.389 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 4.078970e-01 | 0.389 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 4.078970e-01 | 0.389 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.078970e-01 | 0.389 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 4.096688e-01 | 0.388 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 4.155386e-01 | 0.381 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 4.161914e-01 | 0.381 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 4.161914e-01 | 0.381 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.161914e-01 | 0.381 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.161914e-01 | 0.381 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 4.161914e-01 | 0.381 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 4.161914e-01 | 0.381 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.161914e-01 | 0.381 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 4.171078e-01 | 0.380 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 4.218786e-01 | 0.375 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 4.218786e-01 | 0.375 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 4.218786e-01 | 0.375 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 4.218786e-01 | 0.375 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 4.277188e-01 | 0.369 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 4.277188e-01 | 0.369 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 4.305604e-01 | 0.366 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 4.315435e-01 | 0.365 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 4.319624e-01 | 0.365 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 4.375590e-01 | 0.359 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.400101e-01 | 0.357 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 4.444800e-01 | 0.352 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 4.444800e-01 | 0.352 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.444800e-01 | 0.352 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 4.444800e-01 | 0.352 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 4.444800e-01 | 0.352 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 4.450281e-01 | 0.352 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 4.499109e-01 | 0.347 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 4.499109e-01 | 0.347 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 4.499109e-01 | 0.347 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 4.499109e-01 | 0.347 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 4.499109e-01 | 0.347 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 4.499109e-01 | 0.347 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 4.512945e-01 | 0.346 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 4.512945e-01 | 0.346 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 4.512955e-01 | 0.346 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 4.512955e-01 | 0.346 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 4.608990e-01 | 0.336 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 4.624554e-01 | 0.335 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 4.645951e-01 | 0.333 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 4.712709e-01 | 0.327 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 4.718221e-01 | 0.326 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 4.718221e-01 | 0.326 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 4.718221e-01 | 0.326 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.745081e-01 | 0.324 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 4.745487e-01 | 0.324 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 4.757772e-01 | 0.323 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 4.757772e-01 | 0.323 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 4.757772e-01 | 0.323 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 4.757772e-01 | 0.323 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 4.757772e-01 | 0.323 | 0 | 0 |
| Defective MAT1A causes MATD | R-HSA-5579024 | 4.757772e-01 | 0.323 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 4.757772e-01 | 0.323 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 4.757772e-01 | 0.323 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 4.757772e-01 | 0.323 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 4.757772e-01 | 0.323 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 4.757772e-01 | 0.323 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 4.773718e-01 | 0.321 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 4.773718e-01 | 0.321 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 4.773718e-01 | 0.321 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 4.773718e-01 | 0.321 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 4.797665e-01 | 0.319 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 4.797665e-01 | 0.319 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.797665e-01 | 0.319 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 4.797665e-01 | 0.319 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 4.797665e-01 | 0.319 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 4.797665e-01 | 0.319 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 4.804151e-01 | 0.318 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 4.804151e-01 | 0.318 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 4.808517e-01 | 0.318 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.876618e-01 | 0.312 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 4.920979e-01 | 0.308 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 4.939002e-01 | 0.306 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 4.946707e-01 | 0.306 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 4.974176e-01 | 0.303 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.974176e-01 | 0.303 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 5.041754e-01 | 0.297 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 5.041754e-01 | 0.297 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 5.041754e-01 | 0.297 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 5.041754e-01 | 0.297 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 5.041754e-01 | 0.297 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 5.120806e-01 | 0.291 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 5.136401e-01 | 0.289 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 5.136401e-01 | 0.289 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 5.136401e-01 | 0.289 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 5.136401e-01 | 0.289 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.136401e-01 | 0.289 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 5.136401e-01 | 0.289 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 5.162564e-01 | 0.287 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 5.198484e-01 | 0.284 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.198484e-01 | 0.284 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 5.198484e-01 | 0.284 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 5.198484e-01 | 0.284 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.213341e-01 | 0.283 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 5.221675e-01 | 0.282 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 5.238075e-01 | 0.281 | 0 | 0 |
| Immune System | R-HSA-168256 | 5.246193e-01 | 0.280 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 5.247845e-01 | 0.280 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 5.292846e-01 | 0.276 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 5.292846e-01 | 0.276 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 5.292846e-01 | 0.276 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 5.292846e-01 | 0.276 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 5.292846e-01 | 0.276 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 5.292846e-01 | 0.276 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 5.292846e-01 | 0.276 | 0 | 0 |
| Toxicity of botulinum toxin type G (botG) | R-HSA-5250989 | 5.292846e-01 | 0.276 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.292846e-01 | 0.276 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.292846e-01 | 0.276 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.292846e-01 | 0.276 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 5.292846e-01 | 0.276 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 5.292846e-01 | 0.276 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.292846e-01 | 0.276 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 5.302500e-01 | 0.276 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 5.302500e-01 | 0.276 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 5.302500e-01 | 0.276 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 5.302500e-01 | 0.276 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 5.302500e-01 | 0.276 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 5.325645e-01 | 0.274 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 5.414931e-01 | 0.266 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 5.417937e-01 | 0.266 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 5.417937e-01 | 0.266 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 5.417937e-01 | 0.266 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 5.417937e-01 | 0.266 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 5.460217e-01 | 0.263 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.460217e-01 | 0.263 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 5.460217e-01 | 0.263 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 5.460217e-01 | 0.263 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 5.460217e-01 | 0.263 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.460217e-01 | 0.263 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 5.460217e-01 | 0.263 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 5.463932e-01 | 0.262 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 5.506105e-01 | 0.259 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 5.510205e-01 | 0.259 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 5.555373e-01 | 0.255 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 5.555373e-01 | 0.255 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 5.588859e-01 | 0.253 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 5.588859e-01 | 0.253 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 5.632131e-01 | 0.249 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 5.699141e-01 | 0.244 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 5.699141e-01 | 0.244 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 5.748118e-01 | 0.240 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 5.768629e-01 | 0.239 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 5.768629e-01 | 0.239 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 5.768629e-01 | 0.239 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 5.768629e-01 | 0.239 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 5.768629e-01 | 0.239 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 5.768629e-01 | 0.239 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 5.768629e-01 | 0.239 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 5.773334e-01 | 0.239 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 5.773334e-01 | 0.239 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 5.773334e-01 | 0.239 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 5.773334e-01 | 0.239 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 5.773334e-01 | 0.239 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 5.773334e-01 | 0.239 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 5.773334e-01 | 0.239 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 5.773334e-01 | 0.239 | 0 | 0 |
| Proton/oligopeptide cotransporters | R-HSA-427975 | 5.773334e-01 | 0.239 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 5.773334e-01 | 0.239 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 5.773334e-01 | 0.239 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 5.773334e-01 | 0.239 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 5.773334e-01 | 0.239 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 5.773334e-01 | 0.239 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 5.773334e-01 | 0.239 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 5.773334e-01 | 0.239 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 5.773334e-01 | 0.239 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 5.805157e-01 | 0.236 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 5.840718e-01 | 0.234 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 5.883270e-01 | 0.230 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 5.883270e-01 | 0.230 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 6.005671e-01 | 0.221 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 6.035765e-01 | 0.219 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 6.043411e-01 | 0.219 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 6.043411e-01 | 0.219 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 6.043411e-01 | 0.219 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 6.043411e-01 | 0.219 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 6.061408e-01 | 0.217 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 6.061408e-01 | 0.217 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 6.061408e-01 | 0.217 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.061408e-01 | 0.217 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 6.061408e-01 | 0.217 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 6.064171e-01 | 0.217 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 6.126265e-01 | 0.213 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 6.163481e-01 | 0.210 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.163481e-01 | 0.210 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 6.182740e-01 | 0.209 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 6.204800e-01 | 0.207 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 6.204800e-01 | 0.207 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.204800e-01 | 0.207 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 6.204800e-01 | 0.207 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 6.204800e-01 | 0.207 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 6.204800e-01 | 0.207 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 6.204800e-01 | 0.207 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 6.204800e-01 | 0.207 | 0 | 0 |
| Lactose synthesis | R-HSA-5653890 | 6.204800e-01 | 0.207 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 6.204800e-01 | 0.207 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 6.204800e-01 | 0.207 | 0 | 0 |
| Metabolism of vitamin K | R-HSA-6806664 | 6.204800e-01 | 0.207 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 6.204800e-01 | 0.207 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 6.204800e-01 | 0.207 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.204800e-01 | 0.207 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 6.239843e-01 | 0.205 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 6.239843e-01 | 0.205 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 6.239843e-01 | 0.205 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 6.239977e-01 | 0.205 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 6.239977e-01 | 0.205 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 6.239977e-01 | 0.205 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 6.262677e-01 | 0.203 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 6.262677e-01 | 0.203 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 6.262677e-01 | 0.203 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 6.262677e-01 | 0.203 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 6.262677e-01 | 0.203 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 6.265549e-01 | 0.203 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 6.299269e-01 | 0.201 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 6.338532e-01 | 0.198 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 6.338532e-01 | 0.198 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 6.338532e-01 | 0.198 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 6.338532e-01 | 0.198 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.338532e-01 | 0.198 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 6.338532e-01 | 0.198 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 6.410727e-01 | 0.193 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 6.410727e-01 | 0.193 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 6.430233e-01 | 0.192 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 6.430233e-01 | 0.192 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 6.448624e-01 | 0.191 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 6.480486e-01 | 0.188 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 6.480486e-01 | 0.188 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 6.480486e-01 | 0.188 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 6.480486e-01 | 0.188 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 6.480486e-01 | 0.188 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 6.541498e-01 | 0.184 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 6.554775e-01 | 0.183 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 6.557575e-01 | 0.183 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 6.592245e-01 | 0.181 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 6.592245e-01 | 0.181 | 0 | 0 |
| Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2 | R-HSA-964827 | 6.592245e-01 | 0.181 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.592245e-01 | 0.181 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 6.592245e-01 | 0.181 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 6.592245e-01 | 0.181 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 6.592245e-01 | 0.181 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 6.592245e-01 | 0.181 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 6.592245e-01 | 0.181 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 6.592245e-01 | 0.181 | 0 | 0 |
| SLC-mediated transport of oligopeptides | R-HSA-9959399 | 6.592245e-01 | 0.181 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 6.592245e-01 | 0.181 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.592245e-01 | 0.181 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 6.592245e-01 | 0.181 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 6.592245e-01 | 0.181 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 6.592245e-01 | 0.181 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 6.592245e-01 | 0.181 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.592245e-01 | 0.181 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 6.592245e-01 | 0.181 | 0 | 0 |
| Maturation of replicase proteins | R-HSA-9694301 | 6.592245e-01 | 0.181 | 0 | 0 |
| Disease | R-HSA-1643685 | 6.600112e-01 | 0.180 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 6.600145e-01 | 0.180 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 6.600145e-01 | 0.180 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 6.608210e-01 | 0.180 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 6.689106e-01 | 0.175 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 6.689106e-01 | 0.175 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 6.689106e-01 | 0.175 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 6.689106e-01 | 0.175 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 6.689106e-01 | 0.175 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 6.737635e-01 | 0.171 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 6.755107e-01 | 0.170 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 6.791318e-01 | 0.168 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.807982e-01 | 0.167 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.846527e-01 | 0.165 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 6.846527e-01 | 0.165 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 6.852100e-01 | 0.164 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 6.888520e-01 | 0.162 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 6.888520e-01 | 0.162 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 6.888520e-01 | 0.162 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 6.888520e-01 | 0.162 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 6.888520e-01 | 0.162 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 6.893480e-01 | 0.162 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 6.893480e-01 | 0.162 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 6.919185e-01 | 0.160 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 6.940156e-01 | 0.159 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 6.940156e-01 | 0.159 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 6.940156e-01 | 0.159 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 6.940156e-01 | 0.159 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 6.940156e-01 | 0.159 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 6.940156e-01 | 0.159 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 6.940156e-01 | 0.159 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 6.940156e-01 | 0.159 | 0 | 0 |
| Toxicity of botulinum toxin type B (botB) | R-HSA-5250958 | 6.940156e-01 | 0.159 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 6.940156e-01 | 0.159 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 6.940156e-01 | 0.159 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 6.940156e-01 | 0.159 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 6.940156e-01 | 0.159 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 6.940156e-01 | 0.159 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 6.940156e-01 | 0.159 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 6.940156e-01 | 0.159 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 6.940156e-01 | 0.159 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 6.940156e-01 | 0.159 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 6.940156e-01 | 0.159 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 6.940156e-01 | 0.159 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 6.940156e-01 | 0.159 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 7.058098e-01 | 0.151 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 7.078059e-01 | 0.150 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 7.078772e-01 | 0.150 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 7.078772e-01 | 0.150 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 7.078772e-01 | 0.150 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 7.078772e-01 | 0.150 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 7.126081e-01 | 0.147 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 7.126081e-01 | 0.147 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 7.126081e-01 | 0.147 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 7.127755e-01 | 0.147 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 7.189702e-01 | 0.143 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.224996e-01 | 0.141 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 7.252566e-01 | 0.140 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 7.252566e-01 | 0.140 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 7.252566e-01 | 0.140 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 7.252566e-01 | 0.140 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 7.252566e-01 | 0.140 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.252566e-01 | 0.140 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.252566e-01 | 0.140 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 7.252566e-01 | 0.140 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 7.252566e-01 | 0.140 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 7.252566e-01 | 0.140 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.252566e-01 | 0.140 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.252566e-01 | 0.140 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 7.252566e-01 | 0.140 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 7.252566e-01 | 0.140 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 7.252566e-01 | 0.140 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 7.252566e-01 | 0.140 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 7.252566e-01 | 0.140 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 7.259959e-01 | 0.139 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 7.295205e-01 | 0.137 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 7.295205e-01 | 0.137 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 7.295205e-01 | 0.137 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 7.295205e-01 | 0.137 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 7.295205e-01 | 0.137 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 7.330243e-01 | 0.135 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 7.341399e-01 | 0.134 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 7.386368e-01 | 0.132 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.418464e-01 | 0.130 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 7.432221e-01 | 0.129 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 7.432221e-01 | 0.129 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 7.432221e-01 | 0.129 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 7.434512e-01 | 0.129 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 7.434512e-01 | 0.129 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 7.434512e-01 | 0.129 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 7.465221e-01 | 0.127 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.498489e-01 | 0.125 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 7.498489e-01 | 0.125 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 7.498489e-01 | 0.125 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 7.533096e-01 | 0.123 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 7.533096e-01 | 0.123 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 7.533096e-01 | 0.123 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 7.533096e-01 | 0.123 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 7.533096e-01 | 0.123 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 7.533096e-01 | 0.123 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.533096e-01 | 0.123 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 7.533096e-01 | 0.123 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 7.533096e-01 | 0.123 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 7.533096e-01 | 0.123 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 7.533096e-01 | 0.123 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 7.578979e-01 | 0.120 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 7.578979e-01 | 0.120 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 7.595738e-01 | 0.119 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 7.595738e-01 | 0.119 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 7.627908e-01 | 0.118 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 7.627908e-01 | 0.118 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 7.688477e-01 | 0.114 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 7.688477e-01 | 0.114 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 7.688477e-01 | 0.114 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 7.688477e-01 | 0.114 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 7.688477e-01 | 0.114 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 7.688477e-01 | 0.114 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 7.688477e-01 | 0.114 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 7.717064e-01 | 0.113 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 7.717064e-01 | 0.113 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 7.717064e-01 | 0.113 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.717064e-01 | 0.113 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 7.717064e-01 | 0.113 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 7.717064e-01 | 0.113 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 7.720219e-01 | 0.112 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 7.747840e-01 | 0.111 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 7.750719e-01 | 0.111 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 7.750719e-01 | 0.111 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 7.784996e-01 | 0.109 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 7.784996e-01 | 0.109 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 7.784996e-01 | 0.109 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.784996e-01 | 0.109 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 7.784996e-01 | 0.109 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 7.784996e-01 | 0.109 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 7.784996e-01 | 0.109 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 7.784996e-01 | 0.109 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 7.784996e-01 | 0.109 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 7.840150e-01 | 0.106 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 7.840150e-01 | 0.106 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 7.855258e-01 | 0.105 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 7.865765e-01 | 0.104 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 7.865765e-01 | 0.104 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 7.865765e-01 | 0.104 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 7.865765e-01 | 0.104 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 7.897400e-01 | 0.103 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 7.974556e-01 | 0.098 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 7.974556e-01 | 0.098 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 8.000738e-01 | 0.097 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 8.011188e-01 | 0.096 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 8.011188e-01 | 0.096 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 8.011188e-01 | 0.096 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 8.011188e-01 | 0.096 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 8.011188e-01 | 0.096 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 8.011188e-01 | 0.096 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 8.011188e-01 | 0.096 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 8.011188e-01 | 0.096 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 8.011188e-01 | 0.096 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.011188e-01 | 0.096 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 8.030963e-01 | 0.095 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 8.030963e-01 | 0.095 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 8.030963e-01 | 0.095 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 8.030963e-01 | 0.095 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 8.030963e-01 | 0.095 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 8.030963e-01 | 0.095 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 8.036036e-01 | 0.095 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 8.036036e-01 | 0.095 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 8.070631e-01 | 0.093 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 8.094236e-01 | 0.092 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 8.166902e-01 | 0.088 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.166902e-01 | 0.088 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 8.170611e-01 | 0.088 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 8.184693e-01 | 0.087 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 8.208078e-01 | 0.086 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.214294e-01 | 0.085 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 8.214294e-01 | 0.085 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 8.214294e-01 | 0.085 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.214294e-01 | 0.085 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.214294e-01 | 0.085 | 0 | 0 |
| Acetylation | R-HSA-156582 | 8.214294e-01 | 0.085 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 8.214294e-01 | 0.085 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 8.214294e-01 | 0.085 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.214294e-01 | 0.085 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.214294e-01 | 0.085 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 8.214294e-01 | 0.085 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 8.214294e-01 | 0.085 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.214294e-01 | 0.085 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 8.214294e-01 | 0.085 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 8.214294e-01 | 0.085 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 8.214294e-01 | 0.085 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 8.252676e-01 | 0.083 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 8.271308e-01 | 0.082 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 8.274181e-01 | 0.082 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 8.316247e-01 | 0.080 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 8.335207e-01 | 0.079 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 8.367459e-01 | 0.077 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 8.396668e-01 | 0.076 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.396668e-01 | 0.076 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 8.396668e-01 | 0.076 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 8.396668e-01 | 0.076 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.396668e-01 | 0.076 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 8.406462e-01 | 0.075 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 8.406462e-01 | 0.075 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 8.406462e-01 | 0.075 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 8.459183e-01 | 0.073 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 8.459183e-01 | 0.073 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.460215e-01 | 0.073 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 8.546603e-01 | 0.068 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.546603e-01 | 0.068 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 8.560426e-01 | 0.068 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 8.560426e-01 | 0.068 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 8.560426e-01 | 0.068 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 8.560426e-01 | 0.068 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.560426e-01 | 0.068 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 8.560426e-01 | 0.068 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 8.560426e-01 | 0.068 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 8.560426e-01 | 0.068 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.560426e-01 | 0.068 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.560426e-01 | 0.068 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 8.570178e-01 | 0.067 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 8.583220e-01 | 0.066 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 8.583220e-01 | 0.066 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 8.629849e-01 | 0.064 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 8.630220e-01 | 0.064 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.689236e-01 | 0.061 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 8.695764e-01 | 0.061 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.697171e-01 | 0.061 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 8.697171e-01 | 0.061 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 8.697171e-01 | 0.061 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 8.697171e-01 | 0.061 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 8.697171e-01 | 0.061 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.707467e-01 | 0.060 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.707467e-01 | 0.060 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 8.707467e-01 | 0.060 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 8.707467e-01 | 0.060 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.707467e-01 | 0.060 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 8.707467e-01 | 0.060 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.707467e-01 | 0.060 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.707467e-01 | 0.060 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 8.714829e-01 | 0.060 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 8.714829e-01 | 0.060 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 8.714829e-01 | 0.060 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.714829e-01 | 0.060 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 8.802635e-01 | 0.055 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 8.805222e-01 | 0.055 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 8.839497e-01 | 0.054 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 8.839497e-01 | 0.054 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 8.839497e-01 | 0.054 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 8.839497e-01 | 0.054 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 8.839497e-01 | 0.054 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 8.839497e-01 | 0.054 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 8.839497e-01 | 0.054 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 8.839497e-01 | 0.054 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 8.839497e-01 | 0.054 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 8.855859e-01 | 0.053 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 8.855859e-01 | 0.053 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.856236e-01 | 0.053 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 8.859090e-01 | 0.053 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.866945e-01 | 0.052 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 8.923736e-01 | 0.049 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.929815e-01 | 0.049 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 8.958047e-01 | 0.048 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 8.958047e-01 | 0.048 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 8.958047e-01 | 0.048 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 8.958047e-01 | 0.048 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 8.958047e-01 | 0.048 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 8.958047e-01 | 0.048 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 8.958047e-01 | 0.048 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.958047e-01 | 0.048 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 8.958329e-01 | 0.048 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 8.988110e-01 | 0.046 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.990256e-01 | 0.046 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 8.995716e-01 | 0.046 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.000874e-01 | 0.046 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.028184e-01 | 0.044 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.046709e-01 | 0.044 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.049115e-01 | 0.043 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.064493e-01 | 0.043 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.064493e-01 | 0.043 | 0 | 0 |
| GDP-fucose biosynthesis | R-HSA-6787639 | 9.064493e-01 | 0.043 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.064493e-01 | 0.043 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.064493e-01 | 0.043 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 9.064493e-01 | 0.043 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 9.064493e-01 | 0.043 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.064493e-01 | 0.043 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.064493e-01 | 0.043 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.073433e-01 | 0.042 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 9.160071e-01 | 0.038 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 9.160071e-01 | 0.038 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.160071e-01 | 0.038 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.160071e-01 | 0.038 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 9.160071e-01 | 0.038 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 9.160071e-01 | 0.038 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.177300e-01 | 0.037 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.177300e-01 | 0.037 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.197790e-01 | 0.036 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.210992e-01 | 0.036 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 9.220889e-01 | 0.035 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.245888e-01 | 0.034 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 9.245888e-01 | 0.034 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 9.245888e-01 | 0.034 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.245888e-01 | 0.034 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.245888e-01 | 0.034 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.245888e-01 | 0.034 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.245888e-01 | 0.034 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.260522e-01 | 0.033 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.278673e-01 | 0.033 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.286041e-01 | 0.032 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.289744e-01 | 0.032 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.289744e-01 | 0.032 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.293938e-01 | 0.032 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.293938e-01 | 0.032 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.308250e-01 | 0.031 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.322942e-01 | 0.030 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.322942e-01 | 0.030 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 9.322942e-01 | 0.030 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.322942e-01 | 0.030 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.322942e-01 | 0.030 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.337794e-01 | 0.030 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.346019e-01 | 0.029 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 9.346019e-01 | 0.029 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.346019e-01 | 0.029 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.346019e-01 | 0.029 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.392126e-01 | 0.027 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.392126e-01 | 0.027 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 9.392871e-01 | 0.027 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.401199e-01 | 0.027 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 9.425153e-01 | 0.026 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.427369e-01 | 0.026 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.440613e-01 | 0.025 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.440613e-01 | 0.025 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.451935e-01 | 0.024 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 9.454245e-01 | 0.024 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.454245e-01 | 0.024 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.461138e-01 | 0.024 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 9.464767e-01 | 0.024 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.482850e-01 | 0.023 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.498559e-01 | 0.022 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.498559e-01 | 0.022 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.501867e-01 | 0.022 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.502407e-01 | 0.022 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.510019e-01 | 0.022 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.510019e-01 | 0.022 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.510019e-01 | 0.022 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 9.510019e-01 | 0.022 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.522100e-01 | 0.021 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.534723e-01 | 0.021 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.534723e-01 | 0.021 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.541358e-01 | 0.020 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.560096e-01 | 0.020 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 9.560096e-01 | 0.020 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 9.560096e-01 | 0.020 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.560096e-01 | 0.020 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.560096e-01 | 0.020 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 9.560096e-01 | 0.020 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.560096e-01 | 0.020 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.560096e-01 | 0.020 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.565116e-01 | 0.019 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.568440e-01 | 0.019 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 9.580692e-01 | 0.019 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.580692e-01 | 0.019 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.605058e-01 | 0.017 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.605058e-01 | 0.017 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 9.605058e-01 | 0.017 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.610316e-01 | 0.017 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 9.616761e-01 | 0.017 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 9.616761e-01 | 0.017 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.616761e-01 | 0.017 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.620901e-01 | 0.017 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.623954e-01 | 0.017 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.645427e-01 | 0.016 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 9.645427e-01 | 0.016 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.645427e-01 | 0.016 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.645427e-01 | 0.016 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 9.645427e-01 | 0.016 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.645427e-01 | 0.016 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.655776e-01 | 0.015 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.664448e-01 | 0.015 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.669771e-01 | 0.015 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.680163e-01 | 0.014 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.681672e-01 | 0.014 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.681672e-01 | 0.014 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.681672e-01 | 0.014 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.681672e-01 | 0.014 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.681672e-01 | 0.014 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.704840e-01 | 0.013 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.704840e-01 | 0.013 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 9.714213e-01 | 0.013 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 9.714213e-01 | 0.013 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.714213e-01 | 0.013 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.714213e-01 | 0.013 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.728967e-01 | 0.012 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 9.743430e-01 | 0.011 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 9.743430e-01 | 0.011 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.743430e-01 | 0.011 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.743430e-01 | 0.011 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.743430e-01 | 0.011 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.756698e-01 | 0.011 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.767214e-01 | 0.010 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 9.769661e-01 | 0.010 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.769661e-01 | 0.010 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.769661e-01 | 0.010 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.778023e-01 | 0.010 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.779767e-01 | 0.010 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.793212e-01 | 0.009 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.793212e-01 | 0.009 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.812177e-01 | 0.008 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.812177e-01 | 0.008 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 9.814356e-01 | 0.008 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 9.850383e-01 | 0.007 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.850383e-01 | 0.007 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.860212e-01 | 0.006 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.869491e-01 | 0.006 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.879421e-01 | 0.005 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.879421e-01 | 0.005 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 9.879421e-01 | 0.005 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 9.884009e-01 | 0.005 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.891754e-01 | 0.005 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.891754e-01 | 0.005 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.891754e-01 | 0.005 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 9.891754e-01 | 0.005 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.893769e-01 | 0.005 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.895477e-01 | 0.005 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.902826e-01 | 0.004 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.902826e-01 | 0.004 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.912766e-01 | 0.004 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.912766e-01 | 0.004 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.912766e-01 | 0.004 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.912766e-01 | 0.004 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.913687e-01 | 0.004 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.916185e-01 | 0.004 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 9.921690e-01 | 0.003 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.921690e-01 | 0.003 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.922922e-01 | 0.003 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.929702e-01 | 0.003 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.935149e-01 | 0.003 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.936894e-01 | 0.003 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.936894e-01 | 0.003 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.938913e-01 | 0.003 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.940029e-01 | 0.003 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.941570e-01 | 0.003 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.943351e-01 | 0.002 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.945464e-01 | 0.002 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.949147e-01 | 0.002 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.949147e-01 | 0.002 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.950414e-01 | 0.002 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.950937e-01 | 0.002 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.954304e-01 | 0.002 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.954351e-01 | 0.002 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.958656e-01 | 0.002 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.960501e-01 | 0.002 | 1 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.963216e-01 | 0.002 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.966981e-01 | 0.001 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.972081e-01 | 0.001 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.972081e-01 | 0.001 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.973394e-01 | 0.001 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.974644e-01 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.974644e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.976118e-01 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.978563e-01 | 0.001 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.980266e-01 | 0.001 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.981020e-01 | 0.001 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.981020e-01 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.981020e-01 | 0.001 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.981357e-01 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.982727e-01 | 0.001 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.982727e-01 | 0.001 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.984364e-01 | 0.001 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.984974e-01 | 0.001 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.985811e-01 | 0.001 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.987125e-01 | 0.001 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.988788e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.989936e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.992491e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.994137e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.994661e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.995277e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.995761e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.995774e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.995943e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.996027e-01 | 0.000 | 0 | 0 |
| Classical antibody-mediated complement activation | R-HSA-173623 | 9.996738e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.996783e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.997021e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.997784e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.997956e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.998562e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.998664e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.998953e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999004e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999074e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999163e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999326e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999326e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999528e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999552e-01 | 0.000 | 0 | 0 |
| Creation of C4 and C2 activators | R-HSA-166786 | 9.999598e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999757e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999809e-01 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.999838e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999846e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999867e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999904e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999905e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999923e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999931e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999941e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999946e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999952e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999954e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999955e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.999960e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999963e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999964e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999968e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999979e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999979e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999979e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999980e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999981e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999990e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.999996e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.999996e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.999999e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 1 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |